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ABSTRACT 
 
 The regenerative capacity of mature mammalian CNS neurons after axonal injury 
is severely limited by a variety of mechanisms.  Retrograde repression is the continuous 
inhibition of the expression of growth phenotypes by tonic signals produced by target 
tissues and transmitted to the neuron cell body via retrograde axonal transport.  Loss of 
target contact through axonal injury is thought to interrupt this retrograde signal and 
allow the up-regulation of growth-associated proteins.  Most CNS neurons, however, 
possess many widespread axon collaterals, such that retrograde repression is maintained 
by intact sustaining collaterals even if some axons are injured. 
 In this project we investigated whether or not retrograde repression plays a role in 
limiting the expression of GAP-43 in transcallosal neurons.  Because TCNs possess local 
axon collaterals to nearby cortex and project distal axons to homologous areas of 
contralateral cortex, we hypothesized that the simultaneous interruption of retrograde 
repressive signals from both ipsilateral and contralateral cortex would result in an up-
regulation of GAP-43 expression in at least some TCNs. 
 We found that a bilateral infusion of a function blocking antibody to FGF-2 into 
the parietal cortex of rats using implanted osmotic mini-pumps resulted in a significant 
increase in the level of expression of GAP-43 mRNA in TCNs identified by retrograde 
fluorescent labeling.  In contrast, neither ipsilateral or contralateral antibody infusions 
alone increased GAP-43 expression significantly compared to controls.  The level of 
expression of GAP-43 in TCNs did not significantly increase after stereotactic 
callosotomy alone, but callosotomized animals treated with an ipsilateral infusion of anti-
FGF-2 had levels of increased GAP-43 expression equivalent to those seen in animals 
that had received bilateral antibody infusions. 
 We conclude that FGF-2 provides a retrograde repressive signal for at least some 
mature mammalian TCNs, and that the expression of growth-associated proteins can be 
up-regulated in CNS neurons by simultaneously blocking retrograde repressive signals 
from all existing axon collaterals.  The ability to alter the gene expression of mature CNS 
neurons in both normal and injured states through the targeted infusion of a 
pharmacological agent may have potential clinical implications in the future. 
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BACKGROUND 
 
 
1.0  INTRODUCTION 
 
 The human central nervous system is arguably the most complex entity in the 
natural world.  Several kilograms of neurons and associated glia, projecting elaborate 
arborizations of axons and dendrites to form endlessly interconnected circuits, from 
which emerges coordinated movement, memory, language, emotion, symbolic thought, 
and consciousness.  This system, however, possesses one great weakness, for its 
regenerative capacity is severely constrained.  After maturity, only a tiny fraction of the 
neurons destroyed by traumatic or degenerative processes and other environmental insults 
can be replaced by the production of new cells.  Damaged axons are unable to regenerate.  
Disrupted connections can rarely be restored.   
 This limitation of regeneration has profound implications for the outcome and 
prognosis of traumatic and metabolic injuries to the brain and spinal cord.  Clinicians 
have long known that the prospect for recovery after injuries to the central nervous 
system is almost universally grim.  Plastic rearrangement of undamaged circuitry to 
restore lost functions can occur, but only to a very limited degree.  The cost to society of 
brain and spinal cord injury, which frequently affect young individuals in the prime of 
their productive years, is incalculable.   Thus there is much interest in neuroscience 
research to elucidate the mechanisms that regulate the growth and regeneration of axons, 
and ultimately develop therapeutic interventions than can promote axon regeneration 
after brain and spinal cord injury in such a way that allows for the recovery of lost 
functionality.   
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1.1  RESPONSES TO AXONAL INJURY:  AN OVERVIEW OF NORMAL AXONAL 
REGENERATION  
 
 Successful regeneration after axonal injury requires a sequence of interrelated 
events.  First, the injured neurons have to survive the acute phase of the injury.  Second, 
they must activate the necessary genetic programs to produce a phenotype capable of 
regeneration.  Third, the regenerating axons have to navigate long distances back to the 
appropriate target tissues.  Finally, once there they then have to reconstitute functional 
synaptic connections.  Only if all these steps are satisfactorily completed will the injured 
neurons be able to regain their lost functionality. 
 Virtually all neuron types with axons projecting out into the peripheral nervous 
system (PNS) display a typical metabolic response and are capable of undergoing lengthy 
regenerative growth following axotomy.  While the distal axon stump commences a 
process of active degeneration known as Wallerian degeneration, and inflammatory cells 
infiltrate the injury site, the neuron cell body undergoes a sequence of changes, known as 
chromatolysis, whereby the cell body swells in size, the nucleus moves to an eccentric 
position, and the nissl substance moves to the periphery of the cytoplasm.  Local 
presynaptic processes may detach from the neuron cell body and its dendritic tree.  After 
a few days, rates of mRNA and protein synthesis increase, marking the activation of 
genetic programs for the regenerative phenotype. (Grafstein, 1975)  At this point, injured 
neurons may initiate axonal regeneration, enter a stable quiescent state, or progress to 
apoptotic cell death.  Target-derived trophic factors appear to play a role in neuron 
survival. (Grafstein, 1975; Hall, 2005) More proximal axotomies tend to be more likely 
to result in neuronal death, and neurons possessing intact axon collaterals are also more 
likely to survive.  Axon sprouts can appear at the proximal stump within hours of 
axotomy, and if the regenerative phenotype is successfully initiated, axon elongation will 
initiate in days. (Hall, 2005)  
 In peripheral nerves, regenerating axons follow the now emptied fascicles of the 
distal nerve stump back to the target tissue, provided the nerve itself remains intact, or 
has been surgically repaired.  Pathfinding failure may result in non-functional aberrant 
reinnervation, or painful neuromas. 
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 In contrast to PNS neurons with their robust regenerative capability, mammalian 
central nervous system (CNS) neurons almost always fail to regenerate injured axons.  
Some CNS neurons progress to cell death or atrophy, while many others exhibit no 
response of any kind, with no evidence of chromatolysis.(Grafstein, 1975)  Even if 
regeneration initiates at the axon stump, regrowth beyond the injury site almost never 
occurs.(Skene, 1984; Yiu and He, 2006) 
 Why should the regenerative capacity of CNS neurons be so limited compared to 
neurons of the PNS?  An individual neuron’s ability to regenerate axons appears to be 
dependent on a wide range of intrinsic and extrinsic factors.  Clearly, different types of 
neurons possess differing capacities for axon regeneration.  For example, embryonic or 
developing neurons are more capable of regeneration than mature neurons, and the CNS 
neurons of anamniotes (fish and amphibians) are more capable of regeneration than the 
CNS neurons of amniotes (reptiles, birds, and mammals).(Skene, 1984)   
 Extrinsic factors in the neuronal microenvironment also play an important role in 
determining the capacity of a neuron to regenerate, and can account for some of the 
observed differences in the regenerative abilities of PNS versus CNS neurons.  Unlike 
CNS neurons, whose axons all terminate exclusively within the CNS itself, PNS neurons 
possess axons that terminate in target tissues both inside and outside the CNS, and are 
thus exposed to regulatory factors external to the CNS.  One crucial difference is the 
nature of the glial cells associated with these two types of neurons.  In peripheral nerves, 
denervated Schwann cells rearrange into structures called Bungner bands that provide a 
guiding scaffold for regenerating axon sprouts, (Skene, 1984) and produce substances 
that help to create a temporarily permissive microenvironment for axon regeneration, 
(Hall, 2005) which is usually maintained until successful target re-innervation is 
achieved.(Grafstein, 1975) 
 In contrast, CNS glial cells (oligodendrocytes and astrocytes), do not produce a 
locally permissive environment for regeneration in response to injury, the way Schwann 
cells in the PNS do, (Qiu et al., 2000; Yiu and He, 2006) and in fact tend to be inhibitory 
of axon growth.  In addition, the inflammatory reaction to axon injury in the CNS has 
been shown to generate yet more inhibitory factors that act to prevent axon regeneration. 
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(Bandtlow and Schwab, 2000; Rhodes et al., 2003; Yiu and He, 2006; Zurn and 
Bandtlow, 2006) 
  The final factor affecting successful axon regeneration is time.  There is a limited 
window of opportunity during which axon regeneration needs to be completed.  Neurons 
cannot sustain regenerative phenotypes indefinitely.  Even in the PNS, chronically 
denervated Schwann cells will eventually apoptose,(Hall, 2005) and chronically 
denervated target tissue may eventually lose the ability to accept new synapses.  Thus the 
longer it takes for axon regeneration to be completed, which is affected by factors such as 
the distance the regenerating axons must travel and the ease of navigating to the 
appropriate target tissue, the less the likelihood of a favorable outcome. 
 
1.2  GROWTH ASSOCIATED PROTEINS AND THE GAP HYPOTHESIS 
 Experiments conducted in the early 1980s found that in neurons capable of axon 
regeneration, certain proteins normally not present or present in low concentrations, 
became expressed at high levels in response to axotomy.(Skene and Willard, 1981b)  
Neuron populations that were not capable of regenerating their axons after injury did not 
increase their expression of these same proteins in response to axotomy.(Skene and 
Willard, 1981a; Skene, 1984; Reh et al., 1987)  Further experiments found that these 
same proteins were expressed at high levels in development during periods of axon 
outgrowth in a variety of neuronal populations.(Skene and Willard, 1981a; Kalil and 
Skene, 1986; Skene, 1989)  Thus it appeared that axonal regeneration and developmental 
axon growth were related phenomena, dependent on the same set of genes, and that 
regeneration may be considered in many senses as a recapitulation of developmental 
growth. 
 These proteins became known collectively as growth-associated proteins (GAPs).  
Some of the first GAPs to be characterized were membrane bound proteins that were 
rapidly transported to growing axon terminals.(Skene and Willard, 1981a)  The observed 
timing of the up-regulation and down-regulation of various GAPs also coincided with the 
various observed stages of axon elongation, branching, and synapse formation.(Skene, 
1989)  These and other experimental findings lead to the development of the GAP 
hypothesis.  Namely, that GAPs play essential roles in axon outgrowth and regeneration, 
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and their expression is required for successful axonal growth or regeneration.  GAP 
expression creates the growth phenotype used by all neurons during development of their 
axon arbors, and neurons regenerate injured axons by reactivating, in part or in whole, 
this developmental growth phenotype.  Those neurons which are incapable of axon 
regeneration, such as adult mammalian CNS neurons, are neurons which either cannot or 
are somehow prevented from up-regulating GAP expression in response to axonal injury.  
In order to understand the process of axon regeneration, it is therefore necessary to 
understand how axons grow during development. 
 
1.3  AN OVERVIEW OF DEVELOPMENTAL AXON GROWTH AND 
PATHFINDING  
 
1.3.1  The Initiation of Axon Outgrowth and the Establishment of Neuronal Polarity 
 During development, most CNS neurons are born in ventricular or paraventricular 
proliferative zones, and then migrate sometimes substantial distances to their final 
destinations, following a variety of physical and chemical cues.  For example, pyramidal 
projection neurons are generated in the ventricular zone and migrate outwards to 
assemble the six layers of the mammalian neocortex in an inside to outside fashion, such 
that deeper layers are comprised of the oldest cells.  In contrast, nonpyramidal neurons 
that will perform inhibitory functions in cerebral cortex are generated in the 
paraventricular ganglionic eminences and migrate tangentially to their final 
locations.(Bielas et al., 2004) 
 Neurons begin differentiating soon after completing migration, and start to 
elaborate the many cellular processes that will become dendrites and axons in maturity.  
The typical CNS neuron possesses a single axon which may or may not have branches, 
and many dendrites arising from the main cell body.(Dotti and Banker, 1987)  The 
establishment of this polarity is one of the first steps in axon growth.  In vitro 
experiments with hippocampal(Dotti et al., 1988) and cortical(Kalil et al., 2000) neurons 
reveal that at least for these two neuronal subpopulations in cell culture, the mature 
polarized form is acquired via a stereotyped sequence of developmental events.  Multiple 
minor processes start to grow out from the neuron cell body, and are at first 
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indistinguishable from one another.  At some point, one of the minor processes becomes 
selected for an axonal fate, and its growth rate is accelerated while the growth of the 
remaining minor processes is suppressed.  After this process differentiates into the axon, 
the remaining minor processes begin growing again, and eventually become 
dendrites.(Dotti et al., 1988) 
 
1.3.2 Axon Pathfinding During Development 
 The axons of CNS projection neurons often must traverse long and frequently 
convoluted paths to reach distant innervation targets, with multiple bends and sharp turns. 
The developmental mechanisms by which these axons find their way to their targets 
remain an area of considerable research.   
 Axon elongation and pathfinding is a function of the growth cone, a motile 
structure at the tip of the growing axon.  Morphologically, the growth cone is a 
cytoplasmic swelling possessing multiple lamellipodia.  As the growth cone migrates, it 
lays down the axon behind it along the path it travels.  The course of the mature axon 
thus reflects the path that the growth cone navigated in development from the neuron cell 
body to the target tissue. 
   The growth cone’s morphology has been observed to increase in complexity 
whenever and wherever a growing axon is required to make important directional 
decisions.(Dingwell et al., 2000)  Morphologically complex lamellipodia extending in 
different directions appear to compete with one another until a new direction becomes 
selected and the lamellipodia heading in other directions are retracted.  As the growth 
cone flows in the selected direction, the microtubule array in its base is reoriented in the 
new direction and subsequently is assembled into a new segment of axon as the growth 
cone passes.  This process continuously repeats itself to lay down further segments of 
axon until the whole process is halted when the axons approach appropriate target 
tissues.(Brandt, 1998) 
 The available evidence suggests that growth cones make navigational decisions 
based on various cues they sense in the microenvironments they traverse.  Mechanisms 
implicated in growth cone guidance include adherence to preferred physical substrates, 
and attraction to or repulsion by chemotactic substances, both membrane-bound and in 
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soluble diffusion gradients.  Several families of molecules have been identified that have 
effects on growth cone navigation and the growth cones’ responses to these 
environmental cues can also be variable and time dependent.  The growth cone of one 
axon can be attracted to a substance during one period of growth and repelled during 
another, or become sensitive to a certain substance only during specific periods of 
time.(Brandt, 1998; Dingwell et al., 2000; Cooper, 2002)  Changes in responsiveness to 
various substances can be mediated by yet other environmental cues, or may constitute 
part of an intrinsic program in the neuron itself.  In some axon tracts, the first pioneering 
fibers to reach a target site become an additional guidance mechanism in their own right, 
forming a physical substrate that subsequent axons can follow through cell adhesion to 
the same target site. (Richards, 2002) 
 The axons of different populations of neurons use different combinations of these 
mechanisms to reach their target sites.  The guidance of axons to their target sites is an 
intricate process requiring precise timing and coordination of multiple developmental 
processes in the neurons themselves, the target site, and in all the tissues traversed by the 
axons during their growth.  The exact sequence of events is specific for each individual 
neuronal subpopulation, and the majority of these sequences remain unknown. 
   
1.3.3 The Development of Axon Collateral Branches 
 Neurons may elaborate axon arbors with multiple collateral branches to different 
distant target sites.  Collateral branching also plays an important role in target recognition 
in many populations of cortical neurons.  In these neurons, axons are frequently observed 
to overshoot their ultimate targets, only to later grow collateral branches into the target, 
followed by retraction of the overshot portion of the axon, and further selective 
refinement of the axon arborization.(Kalil et al., 2000) 
 Early observations suggested that axon collaterals do not form, as one might at 
first expect, from primary bifurcations of migrating growth cones as is the case in the 
elaboration of terminal arborizations within a target area.(O'Leary and Terashima, 1988)  
Rather, collateral branches appeared to arise from the main axon shaft after the main 
growth cone had already passed and advanced a substantial distance beyond.  More 
detailed observations in both in vivo and in vitro experiments demonstrated that the 
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growth cone actually pauses for significant amounts of time at the sites of future 
collateral branching.  During this period of pausing, the growth cone enlarges, and when 
forward migration resumes, structural elements of the growth cone are left behind, out of 
which the collateral branch later grows, with its own growth cone.(Kalil et al., 2000) 
 Thus it now appears that the formation of axon collaterals does, after all, involve 
what is essentially the bifurcation of the primary growth cone, except that it occurs in a 
delayed fashion.  The pause in the progress of the primary growth cone and its 
subsequent expansion in size appear to allow for the accumulation and rearrangement of 
cytoskeletal elements necessary in creating the new collateral branch and secondary 
growth cone associated with it. 
 Collateral branching appears to be mediated by target derived factors.  
Chemorepulsive factors have been implicated in causing the primary growth cones to 
pause, while chemoattractive gradients play important roles in initiating the growth of 
collateral branches and guiding them to their targets.  The same groups of substances 
implicated in primary axon guidance also appear to be involved in the creation of 
collateral branches.  
 
1.3.4  The Role of GAPs in Axon Outgrowth and Collateral Branching 
 In support of the GAP hypothesis, many of the proteins found to play important 
roles in the assembly and construction of the axon shaft and growth cone, and in 
mediating the sensitivity of the growth cone to guidance cues were subsequently 
identified as GAPs.  That is, they displayed the expression pattern typical of GAPs, in 
which they are expressed at high levels during development and regenerative phases, but 
are down-regulated in mature, functioning neurons.  These proteins included cytoskeletal 
proteins used to assemble the axon shaft and growth cone, proteins involved in 
lamellipodia motility, receptors and other intermediates in signal transduction systems 
associated with guidance cue molecules, and proteins necessary in mediating changes in 
growth cone morphology.(Skene, 1984, 1989; Meiri and Gordon-Weeks, 1990; Jenkins 
and Hunt, 1991; Brandt, 1998; Dingwell et al., 2000; Kalil et al., 2000; Andrews et al., 
2006) 
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 It became clear that the high regenerative capacity of developing neurons was due 
to their high levels of GAP expression, and that the growth phenotype is subsequently 
turned off as developing neurons mature.  Neurons with injured axons had to reactivate 
their developmental growth phenotypes in order to regain the potential for axon 
regeneration.  This explained why neurons that failed to up-regulate GAP expression 
after axon injury also failed to regenerate the injured axons. 
 
1.4  THE ROLE OF GAP-43 IN AXON GROWTH AND REGENERATION 
 
1.4.1 Correlative Observations 
 The protein GAP-43, also known variously as pp46, B50, F1, and neuromodulin, 
was one of the first discovered and best characterized of the growth associated 
proteins.(Meiri et al., 1986; Benowitz and Routtenberg, 1997)  Not long after GAP-43 
was first associated with axonal growth and regeneration,(Skene and Willard, 1981a) it 
was determined that the protein was very similar in its properties to proteins that had 
been previously identified, characterized, and named in a variety of other contexts.  It 
was eventually determined by sequencing that all these proteins were, in fact, the 
same.(Benowitz and Routtenberg, 1997)  After the initial identification of GAP-43 in 
frogs, homologues were discovered in many different vertebrates spanning the 
evolutionary spectrum, including fish, rodents (mice, rats, hamsters), rabbit, cow,(Skene, 
1989) chicken,(Moss et al., 1990) and primates.(Benowitz and Routtenberg, 1997) 
 During development, GAP-43 was found to be expressed in high levels in 
virtually all neuronal subpopulations in the CNS and PNS.  Some of the places and 
neuronal populations where GAP-43 activity has been studied include retinal ganglion 
cells,(Skene and Willard, 1981a; Reh et al., 1987; Doster et al., 1991; Benowitz et al., 
1998; Sretavan and Kruger, 1998; Soto et al., 2003) corticospinal tract,(Reh et al., 1987; 
Karimi-Abdolrezaee and Schreyer, 2002; Karimi-Abdolrezaee et al., 2002) rubrospinal 
tract,(Tetzlaff et al., 1991; Fernandes et al., 1999) hippocampal neurons,(Goslin et al., 
1988; Goslin and Banker, 1990; Goslin et al., 1990; Aigner et al., 1995; Shen et al., 2002) 
transcallosal neurons,(Shen et al., 2002) purkinje cells,(Dusart et al., 2005) facial motor 
neurons,(Tetzlaff et al., 1991) spinal cord motor neurons,(Bisby et al., 1996; Fernandes et 
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al., 1999) and dorsal root ganglion (DRG).(Bisby, 1988; Schreyer and Skene, 1993; 
Liabotis and Schreyer, 1995)  GAP-43 is substantially down-regulated in most adult CNS 
neuron populations.  Mature neurons that continue to express detectable levels of GAP-
43 include neurons in the thalamus, basal ganglia, hippocampus, and sensory association 
cortex.(Skene, 1989)  Many of these are areas of the central nervous system that possess 
a high degree of plasticity in their synaptic connections throughout adult life, such as 
areas of higher level sensory association cortex and limbic and hippocampal areas 
associated with memory.  However, not all neuron populations known to remain highly 
plastic express elevated levels of GAP-43 in maturity, and not all the areas where GAP-
43 levels are known to remain elevated in the adult are known to possess high degrees of 
plasticity. 
 The beginning of GAP-43 up-regulation in development coincides with the initial 
outgrowth of the axon and in many neurons GAP-43 levels remain elevated up to the 
time of synaptic maturation.(Skene, 1989)  The down-regulation of GAP-43 expression 
appears to occur in two distinct phases, with the first decrease occurring at the time when 
growing axons first begin to contact their target tissue, and a second decrease at the time 
of the maturation of the terminal arborization. (Karimi-Abdolrezaee et al., 2002) 
 In mature neurons capable of axon regeneration, GAP-43 has been shown to be 
up-regulated in response to axotomy to levels equivalent to those seen during 
development.(Skene and Willard, 1981b; Bisby, 1988; Tetzlaff et al., 1991; Fernandes et 
al., 1999; Soto et al., 2003)  In keeping with the GAP hypothesis, mammalian CNS 
neuron are mostly not able to regenerate their axons and do not show elevation of GAP-
43 expression after axotomy.(Kalil and Skene, 1986; Reh et al., 1987)  The reliable 
association observed between elevated expression of GAP-43 and axonal growth and 
regeneration has lead to the use of GAP-43 as an experimental marker for the neuronal 
axon growth and regeneration phenotype, regardless of the actual function of the GAP-43 
protein. 
 Later discoveries found that there were some mammalian CNS neurons capable of 
up-regulating GAP-43 expression after axotomy.  These included retinal ganglion 
cells(Doster et al., 1991) and the neurons of the rubrospinal tract, (Tetzlaff et al., 1991; 
Fernandes et al., 1999)  Most of these neurons however, still did not normally regenerate 
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their axons, unless a permissive environment was provided, for example by implanting a 
peripheral nerve graft.  Similar findings were observed in experiments with dorsal root 
ganglion (DRG) cells.  Injured central axons of DRG cells could regenerate into a 
peripheral nerve graft when GAP-43 expression in the DRG cell body was highly up-
regulated in response to simultaneous injury of the peripheral axon, but not otherwise. 
(Richardson and Issa, 1984)  Thus, GAP-expression is associated with the ability to 
regenerate axons, but successful regeneration could be thwarted by other environmental 
factors.   
 The distribution of GAP-43 protein within the neuron was also highly suggestive 
of a role in growth and regeneration.  GAP-43 was found to be rapidly 
compartmentalized into axons almost immediately after the establishment of neuronal 
polarity and an axon could be morphologically identified.  GAP-43 levels in the other 
minor processes fell rapidly at this time and GAP-43 became virtually undetectable in the 
dendrites that subsequently developed.(Goslin et al., 1988; Goslin and Banker, 1990; 
Goslin et al., 1990)  Within the axon, GAP-43 was concentrated in the growth 
cone.(Meiri et al., 1986)  More detailed investigations found that within the growth cone, 
GAP-43 was tightly associated with the cell membrane, and more specifically, with the 
membrane skeleton, the network of proteins that supports and stabilizes the cell 
membrane in the growth cone and allow for changes in shape.(Meiri and Gordon-Weeks, 
1990; Moss et al., 1990; Strittmatter et al., 1992)  Furthermore, GAP-43 was most highly 
concentrated in the areas of growth cone membrane that were most tightly adherent to 
physical substrates.(Meiri and Gordon-Weeks, 1990)  Taken together, the localization of 
GAP-43 protein in the growth cone suggested some role in substrate adhesion and 
recognition and the morphological changes required for growth cone motility. 
 
1.4.2  Biochemical and Structural Properties 
 The gene for GAP-43 is found on chromosome 3 in humans and chromosome 16 
in mice.  The first 57 amino acids from the N-terminus are highly conserved in 
vertebrates.  Despite its strong association with the membrane skeleton, GAP-43 does not 
possess a true transmembrane domain.  The membrane binding region is comprised of the 
first ten amino acids of the N-terminus.  Fatty acid chains are known to post-
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translationally modify cysteine residues in the amino terminal, although the role of such 
binding in membrane association remains unclear.(Benowitz and Routtenberg, 1997) 
 GAP-43 is phosphorylated by protein kinase C.  Phosphorylation of GAP-43 has 
been associated with long term potentiation,(Skene, 1989; Benowitz and Routtenberg, 
1997) axon sprouting,(Aigner et al., 1995) and the stimulation of neurite outgrowth by 
cell surface adhesion.(Meiri et al., 1998)   
 Except for the small membrane binding domain, the GAP-43 protein is highly 
hydrophilic, with an acidic isoelectric point of 4.3 to 4.5.  It has an unmodified molecular 
weight of 23.6 kD.  Structurally, GAP-43 extends away from the inner surface of the cell 
membrane and into the cytoplasm, allowing for interactions with cytoskeletal and soluble 
cytoplasmic constituents.  It has also been proposed that GAP-43 might be capable of 
reversibly detaching from the membrane and becoming a soluble protein in the 
cytoplasm.(Skene, 1989) 
 GAP-43 plays a role in a variety of cellular second messenger systems.  It 
interacts with G proteins, and may alter their responsiveness to stimulation by various 
receptors. (Strittmatter et al., 1992)    It is also involved in the phosphatidylinositol 
second messenger system. Unphosphorylated GAP-43 binds calmodulin preferentially in 
the absence of calcium.(Alexander et al., 1987; Benowitz and Routtenberg, 1997)    
 
1.4.3  Genetic Knock-out Studies 
 When GAP-43 expression was inhibited in chick neurons using antisense mRNA, 
the neurons were observed to be able to extend only thin axons with atrophic growth 
cones, which displayed profound defects in their ability to interact with extrinsic 
guidance cues.(Benowitz and Routtenberg, 1997)  Transgenic experiments have lent 
further support to the notion that GAP-43 plays a role in axon pathfinding.  Homozygous 
nonfunctional GAP-43 mouse mutants do not survive long after birth.  In one study, the 
brains of mutant embryos appeared grossly normal, but microscopically had multiple 
aberrations of axon pathfinding in the optic chiasm of their midline crossing fibers, where 
these fibers seemed to wander randomly back and forth across the midline before exiting 
the chiasm.(Sretavan and Kruger, 1998) 
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 In another experiment, homozygous mutants failed to form several major 
commissural tracts, including the anterior commissure, the corpus callosum, and the 
hippocampal commissure. (Shen et al., 2002)  Heterozygous mutants possessing one 
wild-type GAP-43 allele displayed variable phenotypes, with the severity of 
malformations correlating to individual levels of GAP-43 phosphorylation.  GAP-43 
deficient neurons displayed no abnormality in axon elongation compared with wild-type 
neurons, but instead had marked deficiencies in the ability of their axons to fasciculate 
with each other. 
 The impairment of axon fasciculation again suggests a role for GAP-43 in the 
recognition of, binding to, and/or response to physical substrates.  Other experiments lend 
further support to this possibility.  Cerebellar neurons deficient in GAP-43 were found to 
be unable to extend their axons in response to stimulation by the cellular adhesion 
molecule NCAM, although they retained the ability to extend axons in response to other 
known trophic factors.(Meiri et al., 1998) 
 
 
1.5  THE RETROGRADE REPRESSION OF GAP EXPRESSION 
 
1.5.1  GAP-43 Expression is inhibited by target-derived factors 
 As previously stated, the expression of GAP-43 begins to decline at the time when 
target contact starts to be established.  This observation has lead to the speculation that 
the expression of GAP-43 might be regulated by target-derived factors, and lead to the 
development of the concept of retrograde repression as one mechanism accounting for the 
down-regulation of GAP expression in mature neurons.  This is illustrated in figures 1.1 
and 1.2.  Retrograde repression is the continuous inhibition of GAP expression by target-
derived signals that are transmitted to the neuron cell body from the target tissue along 
the axon by retrograde axonal transport.  Axonal injury in responsive neurons interrupts 
this inhibitory signal, which enables the up-regulation of GAP-43 and other growth 
associated proteins, and allows for the initiation of the regenerative phenotype. 
 Experiments have lent support to the theory that retrograde repression plays an 
important role in the regulation of GAP expression in PNS neurons.  When the axons of 
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dorsal root ganglion cells were disrupted by a crush axotomy of the sciatic nerve, 
substantial up-regulation of GAP-43 expression was seen in response, followed by down-
regulation back to baseline levels around the time when target contact was re-established.   
 
 
Figure 1.1:  Retrograde repression of GAP expression during development.  Arrival at the target site brings 
the developing axon into contact with target derived factors that suppress GAP expression and further axon 
growth.  In mature neurons, a tonic inhibition is maintained by continued target contact. 
 
 When the axons were disrupted by a segmental resection of the sciatic nerve that 
prevented successful reinnervation, GAP-43 expression remained high and was not 
down-regulated at the expected time.(Bisby, 1988)  Other experiments found that the 
magnitude of the induction of GAP-43 following axotomy in DRG neurons did not 
depend on the distance of the axotomy from the neuron cell body, suggesting that the 
repressive factor was produced at the target site, rather than somewhere along the course 
of the peripheral nerve.(Liabotis and Schreyer, 1995)  Further experiments with motor 
neurons showed that the retrograde repressive signal was dependent only on target 
contact and not target activity.(Bisby et al., 1996)   
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Figure 1.2:   The interruption of retrograde repression by axonal injury.  The loss of tonic inhibition allows 
for up-regulation of GAP expression and the initiation of axonal regeneration. 
 
 Just as in PNS neurons, the down-regulation of GAP-43 expression during 
development in CNS neurons coincides with the beginning of target contact.(Karimi-
Abdolrezaee et al., 2002)  A delay in the down-regulation of GAP-43 can be observed in 
some corticospinal tract neuron subpopulations if retrograde axonal transport is blocked 
by colchicine during this time period.  When corticospinal tract neurons at an earlier 
stage of development were exposed in vivo to an infusion of a target tissue extract 
obtained from adult spinal cord, a premature down-regulation of GAP-43 expression was 
observed, indicating that a factor present in the adult target tissue does indeed act to 
inhibit GAP expression, and that retrograde axonal transport is required to carry this 
signal to the neuron cell body.(Karimi-Abdolrezaee and Schreyer, 2002) 
  
1.5.2  Retrograde Repression May be Maintained in the CNS by Sustaining Collaterals 
 Dorsal root ganglion (DRG) cells are useful models for studying retrograde 
repression because they possess axons that divide near the cell body into two branches, 
one within the PNS innervating peripheral targets and the other in the CNS projecting 
back into the spinal cord.  Transection of the peripheral branch results in a robust up-
regulation of GAP-43, but transection of the central branch does not.(Schreyer and 
Skene, 1993)   
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 If both axon branches of a DRG neuron are cut, GAP-43 is up-regulated and the 
peripheral axon is regenerated.  The central axon usually does not successfully 
regenerate, but if it is exposed to the favorable environment of a peripheral nerve graft, it 
will grow into the graft. (Richardson and Issa, 1984)  Indeed, even if the central axon is 
not injured, an injury to the peripheral axon can induce the extension of central axons into 
a peripheral nerve graft. (Richardson and Verge, 1986) 
 These experimental findings can be explained by postulating that the peripheral 
axon of the DRG acts as a sustaining collateral that carries retrograde repressive signals 
while the central axon does not.  Thus injury to the central axon alone cannot induce 
GAP-43 up-regulation because the repressive signal continues to be provided by the 
peripheral axon, while injury to the peripheral axon eliminates the retrograde repression, 
allowing the DRG to activate a growth phenotype that can promote the growth of new 
central axons, or possibly even the extension of pre-existing and previously undamaged 
central axons, if a permissive environment is provided. 
  
 
Figure 1.3:  The maintenance of retrograde repression in CNS neurons by multiple sustaining collaterals.  
Distal axotomy does not interrupt retrograde repression from local collaterals. 
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 These observations also suggest a possible contribution of retrograde repression in 
the observed differences in the regenerative capabilities of CNS and PNS neurons.  While 
most PNS neurons elaborate one primary axon with a terminal arborization at its target 
site and few collateral branches, many CNS neurons possess highly complex axon trees 
with collateral branches to both local and distant targets, none of which may be 
considered a primary branch over any of the others.  Thus, CNS neurons may receive 
retrograde repressive signals from more than one, possibly all, of their many axon target 
sites.  A transection of any one of these branches would not result in any change in their 
levels of GAP expression because retrograde repression is maintained by the remaining 
intact collateral branches.  This scenario is illustrated in figure 1.3. 
 In the few CNS neuron populations that have been observed to be capable of up-
regulating GAP expression in response to axotomy with limited regeneration into 
permissive environments, up-regulation of GAP expression and regeneration of axons 
occurred only when the axotomy was performed close to the neuron cell body.  More 
distal axotomies did not result in any up-regulation of GAP expression or any evidence of 
regenerative capacity. (Richardson et al., 1984; Doster et al., 1991; Fernandes et al., 
1999)  This contrasts with PNS neurons, where the distance of the axotomy to the neuron 
cell body has no effect on the subsequent up-regulation of GAPs. (Liabotis and Schreyer, 
1995)  These results may be interpreted as supporting the idea that retrograde repression 
from multiple axon collaterals continues to inhibit GAP expression in CNS neurons after 
axotomy, with only axotomies proximal to the first collateral axon branch being capable 
of inducing an up-regulation of GAPs.  The ability to up-regulate GAPs after proximal 
axotomy has been observed in only some CNS neuron populations.  Proximal axotomy 
experiments are not technically feasible for many CNS neurons.  Also, sustaining 
collaterals do not provide only retrograde repressive signals.  Neurons also receive 
trophic factors from their axon collaterals, and many CNS neurons respond to proximal 
axotomy with atrophy (Dusart et al., 2005) and/or apoptosis.  
 
1.6  HYPOTHESIS PART ONE 
 In this research project, our aim is to investigate the retrograde repression of GAP 
expression in the adult CNS.  If the idea of sustaining collaterals is correct, and 
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retrograde repression operates in the CNS along similar lines to what is known for the 
PNS, except that multiple axon collaterals provide multiple sources of retrograde 
repressive signal at all times, then it should be theoretically possible to induce the up-
regulation of GAPs by completely blocking the retrograde repressive signal from all 
collateral target sites. 
 In order to accomplish this experimentally, it would be necessary to identify and 
experimentally access all the collateral target sites of a given neuron population.  Physical 
axotomy of all axon collaterals of a diverse axon arborization would be problematic in an 
in vivo model, so some biochemical means of blocking the retrograde signal would be 
preferable.  In the most ideal situation, the actual retrograde repressor itself would be 
known and could be targeting specifically. 
 
1.7  THE TRANSCALLOSAL NEURON AS AN EXPERIMENTAL MODEL 
 Neurons which project axons across the corpus callosum to the contralateral 
hemisphere are found throughout the mammalian neocortex.  The vast majority of these 
neurons, known collectively as callosal or transcallosal neurons, (TCN) are prototypical 
pyramidal projection neurons.  Their cell bodies reside primarily in layer III of the 
neocortex in primates, and layers II/III and V in rodents.(Conti and Manzoni, 1994; 
Swanson, 2003) 
 The axons of transcallosal neurons typically form synapses on the dendrite spines 
of other pyramidal neurons, also primarily within cortical layers II and III.(Conti and 
Manzoni, 1994)  It is possible that transcallosal neurons are among the targets of their 
own contralateral counterparts.  In addition to their contralateral projections across the 
corpus callosum, transcallosal neurons also possess multiple axon collaterals to ipsilateral 
targets.  Importantly, transcallosal neurons within the parietal cortex project their distal 
axon collaterals to homologous areas of the contralateral cortex, while their ipsilateral 
collaterals are largely confined to immediately local and nearby areas of the ipsilateral 
neocortex.(Cracco et al., 1989; Thomson and Bannister, 1998; Swanson, 2003)  For 
example, transcallosal neurons in the primary somatosensory cortex possess some 
ipsilateral collaterals projecting into the neighbouring primary motor cortex.(Orihara et 
al., 1997) 
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 During development, TCNs, like all neocortical pyramidal neurons, are born in 
the ventricular zone and migrate outwards along radial glia. (Bielas et al., 2004)  Their 
axons first project ventrally under the influence of semaphorins, then turn medially 
beneath the cingulate cortex.  From the cingulate cortex they turn ventrally to reach the 
corticoseptal boundary, where they make another sharp medial turn to cross the midline.  
Within the contralateral hemisphere, they pass beneath the contralateral cingulate cortex 
and then onwards to their final neocortical targets.  Collateral branches generally grow 
out from the main axon at right angles.   
 A number of midline glial structures appear to provide guidance cues for the 
midline crossing.(Richards, 2002)  Axons from the cingulate cortex may act as 
pioneering fibers for the majority of the other transcallosal axons.  These cingulate 
neurons project axons both medially across the midline and laterally into the ipsilateral 
neocortex, and their projections develop earlier than those of other transcallosal neurons, 
which have been observe to fasciculate with the lateral cingulate fibers to reach the 
cingulate cortex, and then follow the medial cingulate fibers across the midline to form 
the corpus callosum.(Richards, 2002) 
 As previously mentioned, the transcallosal axons are among the telencephalic 
midline crossing projections that appear to depend on the function of GAP-43.  Agenesis 
of the corpus callosum is a fairly common developmental abnormality, associated with 
multiple genetic and structural defects.  In most cases, transcallosal axons reach the 
midline but fail to cross, (Richards, 2002; Shen et al., 2002) indicating that failure of 
midline crossing is the primary deficit underlying these abnormalities.   
 Several neurosurgical procedures in humans involve the division of portions of 
the corpus callosum. For example, anterior corpus callosotomy is indicated for seizure 
control in some circumstances.  Animal studies have shown that transcallosal neurons 
survive for long periods after callosotomy, and display essential no evidence for any 
morphological or metabolic alterations related to either atrophy, degeneration, or axon 
regeneration in response to callosotomy.(Orihara et al., 1997)  It generally appears that 
transcallosal neurons continue to function normally for the most part after callosotomy, 
supporting the idea that they participate in important ipsilateral circuits and possibly 
receive sustaining trophic factors from their ipsilateral targets. 
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 For the purposes of investigating retrograde repression in central nervous system 
neurons, transcallosal neurons offer a number of advantages.  Within the rodent parietal 
cortex, the location of both their ipsilateral and contralateral axon target sites are known, 
being within layers II/III and V of the ipsilateral neocortex in the local area around the 
neuron cell bodies, and the homologous area contralaterally.  These areas are readily 
accessible near the surface of the brain for the application of biochemical agents through 
infusion or injection.  The corpus callosum provides a convenient location for surgical 
lesioning of the contralaterally projecting axons, with callosotomy being a well tolerated 
intervention producing minimal morbidity in experimental animals. 
 
1.8  FGF-2 AS A POTENTIAL RETROGRADE INHIBITOR 
 Basic fibroblast growth factor, bFGF or FGF-2, is a potent neurotrophic factor 
first isolated in mature pituitary and the mature brain,(Gospodarowicz, 1974) and 
subsequently found to be widely distributed in the developing and adult CNS.  FGF-2 
mRNA expression has been detected throughout the developing CNS, with the highest 
levels found in the colliculi, cortex , thalamus, and olfactory bulb.(Ernfors et al., 1990)  
In the mature brain, FGF-2 mRNA has been detected in cortex, hippocampus, 
hypothalamus, and pons.(Emoto et al., 1989) 
 FGF-2 is known to have effects on both neuron and glial differentiation.  It has 
been shown to inhibit the differentiation of OP precursor cells into oligodendrocytes, 
(Zhou and Armstrong, 2007) and regulate neural stems cells during development in a 
complex manner.  Depending on which of a number of known receptors are activated, 
FGF-2 can promote self-renewal, differentiation, or apoptosis of cortical neural stem 
cells.(Maric et al., 2007) 
 FGF-2 is mitogenic for a variety of mesenchyme neuroectoderm derived cell 
types, including fibroblasts and glial cells,(Gospodarowicz, 1974; Davies et al., 1997a)  
and has been demonstrated to promote neuron survival.(Morrison et al., 1986; Johnson-
Farley et al., 2007)  It is also known to stimulate the expression and secretion of nerve 
growth factor by astrocytes in culture.(Yoshida and Gage, 1991) 
 Levels of FGF-2 in mature CNS are persistently increased after cortical injury.  
FGF-2 mRNA expression rises in areas adjacent and ipsilateral to the injury site, and can 
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be detected in ependymal cells of the lateral ventricle, and selected cells in the cortex and 
hippocampus.  FGF-2 can also be found abundantly in the microglia and macrophages 
bordering the injury site.(Frautschy et al., 1991) 
 There is evidence that FGF-2 interacts with GAP-43.  Activation of the FGF 
receptor by FGF-2 results in phosphorylation of GAP-43 in cerebellar granule cells(Meiri 
et al., 1998) and hippocampal neurons.(Tejero-Diez et al., 2000)  The effects of FGF-2 on 
GAP expression and axon growth vary among neuron populations.  There is evidence for 
both negative, positive, and mixed influences.  Unpublished experiments in our 
laboratory have suggested a possible role for FGF-2 as a retrograde inhibitor in DRG 
neurons.  DRG neurons normally express high levels of GAP-43 when grown in culture, 
but GAP-43 expression was greatly diminished if the neurons were cultured in the 
presence of FGF-2.   
 In contrast to the above, FGF-2 promotes axon regeneration in frog retinal 
ganglion cells.  Application of FGF-2 to transected optic nerves increases GAP-43 
expression in the frog retina and affects the distribution of the GAP-43 protein.(Soto et 
al., 2003)  During development, FGF-2 may also be involved in providing pathfinding 
cues guiding retinal ganglion cell axons into the tectum. (Kalil et al., 2000)  In rodent 
motoneurons, treatment with FGF-2 after sciatic nerve transection resulted in a decrease 
in the usual up-regulation of another growth associated protein, alpha-CGRP, but had no 
effect on GAP-43.  Cultured embryonic motoneurons responded to FGF-2 by down-
regulating alpha-CGRP but up-regulated GAP-43.(Piehl et al., 1998) 
 FGF-2 has been shown to promote collateral axon branching in cortical pyramidal 
neurons through a combination of negative and positive effects.  Initially, FGF-2 appears 
to decrease the mobility of the primary growth cone, helping in triggering the pausing 
and subsequent increase in growth cone size that precedes the development of a collateral 
branch.  Later, FGF-2 promotes the extension of those collateral branches.(Kalil et al., 
2000; Szebenyi et al., 2001) 
 For transcallosal neurons, the available evidence suggests that FGF-2 has an 
inhibitory effect in this neuron population.  Experiments with cultured transcallosal 
neurons at different stages of development found that when FGF-2 was added to the 
culture medium, transcallosal neurons in late embryonic and early postnatal stages 
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displayed a marked decrease in neurite outgrowth, axon length, number of minor 
processes and dendrites, and complexity of growth cone filopodia. (Catapano et al., 2004)   
 
1.9  HYPOTHESIS PART TWO 
 Based on the preceding evidence, we formulate for testing the following 
hypothesis:  the expression of the growth associated protein GAP-43 is tonically inhibited 
by target-derived retrograde signals in the CNS in a mechanism similar to that thought to 
operate in the PNS.  In transcallosal neurons, this retrograde repression is provided by 
target factors from both its contralateral and ipsilateral axon collaterals.  One of the 
substances involved in providing this retrograde inhibitory signal for transcallosal 
neurons is FGF-2.  Accordingly, it should be possible to produce an up-regulation of 
GAP-43 expression in this neuron population by simultaneously interrupting FGF-2 
signaling from both distal contralateral and local ipsilateral target sites.  Alternately, a 
unilateral interruption of either the distal or the local target sites in isolation should not 
produce any increase in GAP-43 expression, or at least an increase of lower magnitude. 
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METHODS 
 
2.0  OVERVIEW OF EXPERIMENTAL PLAN 
 
 
Figure 2.1:  Schematic of bilateral infusion experiment.  Anti-FGF-2 is infused into the local ipsilateral and 
homologous distal contralateral axon target sites of fluorescently labeled transcallosal neurons.  Results are 
compared with controls infused with saline buffer alone. 
 
 Transcallosal neurons in the rat parietal cortex were identified using the 
retrograde fluorescent marker Fluorogold™ (Fluorochrome, Denver, CO).  In order to 
determine the role that FGF-2 plays in the retrograde repression of axonal regeneration in 
transcallosal neurons, adult rats were treated with a bilateral, ipsilateral, and contralateral 
infusion of a function blocking antibody to FGF-2 (rabbit IgG, Sigma, K50 = 5.0 ug/mL), 
administered via an implanted osmotic mini-pump, for a period of 7 days.  Levels of 
GAP-43 mRNA in identified TCNs exposed to bilateral, ipsilateral, and contralateral 
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antibody infusion were compared with control animals receiving infusions of buffered 
saline vehicle alone (figures 2.1, 2.2, and 2.3).  
 
Figure 2.2:  Schematic of ipsilateral infusion experiment.  Anti-FGF-2 is infused into the local ipsilateral 
area to block FGF-2 signaling from local axon target sites only. 
 
 
Figure 2.3:  Schematic of contralateral infusion experiment.  Anti-FGF-2 is infused into the homologous 
contralateral target site to block FGF-2 signaling from distal axon target sites only. 
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 To investigate whether or not a blockade of ipsilateral retrograde FGF-2 signaling 
can promote GAP-43 expression after axon injury in transcallosal neurons, a stereotactic 
sectioning of the anterior half of the corpus callosum was performed.  Callosotomized 
animals treated with concurrent ipsilateral infusion of the function blocking antibody to 
FGF-2 were compared to animals subjected to callosotomy alone.  Both these groups 
were also compared with the control, bilateral, ipsilateral and contralateral antibody 
infusion groups already described (figure 2.4). 
 
  
Figure 2.4:  Schematic of callosotomy experiment.  Stereotactic anterior callosotomy interrupts retrograde 
signaling from distal contralateral axon targets, while local FGF-2 signaling from ipsilateral axon target 
sites blocked by an infusion of Anti-FGF-2, or left intact by a sham infusion of saline vehicle. 
 
 In each experimental group, GAP-43 expression was quantified through in-situ 
hybridization of GAP-43 mRNA with a radioactive probe.  Preliminary experiments were 
performed to determine what dose of anti-FGF-2 to use for the main experiments and to 
refine the technique for the stereotactic callosotomy to provide reliable transection of the 
corpus callosum with a minimum of bleeding and surgical morbidity. 
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2.1  CONFIRMATION OF ACTIVITY AND SPECIFICITY OF THE ANTIBODY 
 
2.1.1  Western Blot 
 The specificity of the anti-FGF-2 for FGF-2 in rat cortex was confirmed using a 
Western Blot.  Rat cortex was harvested from a naïve adult rat and homogenized in Lysis 
Buffer (20 mM HEPES pH 7.5, 50 mM KCl, 10% glycerol, 0.5 mM RNase-free EDTA, 
0.5 mM RNase-free EGTA, 1 mM DTT, 1X Sigma anti-protease cocktail).  The 
suspension was spun down at 4000 rpm for 15 minutes, the supernatant collected, and 
spun again at 14 000 rpm for 20 minutes.  A protein bioassay was used to determine the 
total protein concentration (3.9 mg/mL). 
 50 ug of total rat cortex extract protein was loaded onto a 12% Polyacrylamide 
gel, along with 75 and 100 ng of human recombinant FGF-2 in separate lanes and run at 
120V.  The proteins were then transferred from the gel to nitrocellulose membrane at 
120V for 1h.  The nitrocellulose membrane was incubated in blocking solution (3% 
Horse Serum in PBST with 0.5% BSA and 3% milk) for 1 h.  A 1:5000 dilution of the 
antibody was then added to the blocking solution, and incubated overnight at 4°C. 
 The nitrocellulose membrane was washed in PBS for 10 minutes x3, then 
incubated with secondary antibody (IRDye 800CW Donkey anti-Rabbit, LI-COR, 1:10 
000 dilution in blocking solution) for 1 h.  The membrane was washed with PBST for 10 
minutes x2, then PBS for 10 minutes x1.  The membrane was then scanned with a LI-
COR scanner. 
 
2.1.2  Cell Proliferation Assay 
 The function blocking activity of the anti-FGF-2 used in our experiments was 
confirmed using a cell proliferation assay.  3T3 fibroblasts were grown in a 75 mL tissue 
culture flask in DMEM medium containing 5% Horse Serum (5% HS) at 37°C and 0.5% 
CO2  for 24 to 48 h to confluence.  Cells were washed with PBS, and detached by 
incubating at 37°C in 5 mL Versine containing 0.5 mL 1% trypsin for 2 to 3 min.  The 
cell suspension was transferred to a 15 mL eppendorf tube.  The reaction was stopped 
with 1 mL of 5% HS, and medium was added to a total volume of 10 mL.  The cells were 
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spun into a pellet at 800 rpm for 5 minutes, and resuspended in culture medium and 
counted using a hemocytometer. 
 The growth proliferation assay was modified from previously published 
techniques.(Gospodarowicz, 1974; Davies et al., 1997a)  Low densities of cells, 2 x 103 to 
1 x 104 cells/well, were plated onto a 96-well microplate and incubated in DMEM 
medium with 100 uL 0.5% Horse Serum for 48h, at which point the cells had reached 
50% to 70% confluence.  Varying concentrations of human recombinant FGF-2 (Sigma) 
were incubated for 2 h with varying concentrations anti-FGF-2, both diluted in DMEM 
with 0.5% bovine serum albumin to act as a blocking agent, and then 20 uL of the 
combined solution was added to the 96-well microplate.  The cells were then incubated 
with the FGF-2 and antibody for a total of 24 h further.  The cells were pulse labeled with 
BrdU for final 12 h of the incubation. 
 The culture medium was then removed by gently inverting the microplate, and the 
cells were fixed in 100% methanol at -20°C for 1 h.  The wells were washed with PBS x1 
then incubated in 2N HCl with 0.5% TritonX at room temperature for 1 hour to open the 
nuclear membrane.  Afterwards the cells were washed with PBS, pH 8.4 for 5 minutes 
x1, then PBS, pH 7.4 for 10 minutes x 2.  The cells were incubated in blocking solution 
(3% Horse Serum in PBST with 0.5% bovine serum albumin (BSA)) at room temperature 
for 1 h. 
 The cells were incubated for 1 h with primary antibody (mouse anti-BrdU, Sigma, 
1:100 dilution in blocking solution), and then washed with PBS for 5 minutes x3.  The 
cells were then incubated with secondary antibody (IRDye 800CW Goat anti-mouse, LI-
COR, 1:500 dilution in blocking solution) for 1 h, then washed with PBST for 5 minutes 
x2, then PBS for 5 minutes x1.  The plate was read using a LI-COR fluorescent scanner 
and quantified using Odyssey software. 
 
2.2  SURGICAL PROCEDURES 
 
2.2.1  Animal Care and Anaesthesia 
 All procedures using animals were approved beforehand by a local animal care 
committee.  Male Sprague-Daley rats weighing between 250 and 300 g were obtained 
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from Charles River and housed in our laboratories in accordance with the standards of the 
Canadian Council on Animal Care.   
 Anaethesia was induced with halothane inhalation (2% in 100% oxygen) 
administered in an induction chamber and maintained via a respiratory mask fitted over 
the animal’s snout.  Animals were monitored throughout all procedures by observing the 
rate and depth of respiration, the colour of mucous membranes and paw pad skin, and 
pinching the hind paw with forceps.  Halothane levels were adjusted as necessary during 
procedures, with maximum levels never exceeding 2.5%.  Post-operative analgesia was 
provided by subcutaneous injections of 0.5% buprenorphine q8h as needed on post-
operative day 1. 
 Surgical instruments were heat sterilized prior to and after each procedure.  
Aseptic technique was used in all procedures. 
 
2.2.2  Labeling of Transcallosal Neurons with the Retrograde Fluorescent marker 
Fluorogold™ 
 After the administration of halothane anaesthesia, the animal was placed on an 
electric heating pad to prevent hypothermia.  After an adequate depth of anaesthesia was 
confirmed by pinching the hind paw, the head of the animal was immobilized in a 
stereotactic frame (David Kopf Instruments).  The hair over the head was shaved and the 
skin was sterilized with isopropyl alcohol.  Sterile paper towels were laid over the 
animal’s body and the working area to establish a sterile field. 
 A 15 to 20 mm incision was then made with a scalpel in the skin at the midline on 
the top of the head, starting just behind the level of the eyes and extending back beyond 
the level of the external auditory meatus.  The periosteal tissue was dissected free to 
expose the cranium underneath.  A small self-retaining retractor was used to hold back 
the skin edges.  Using an operating microscope, the coronal and sagittal sutures, and the 
Bregma point were identified, and freed of any remaining attached periosteal tissue.  If 
any bleeding was encountered it was soaked up with strips of sterile filter paper or a 
small amount of sterile cotton and pressure applied until hemostasis was restored. 
 Using the stereotactic frame, a point -0.8mm (caudal in the rostro-caudal plane) to 
Bregma and 4.0mm to the right of midline (as marked by the sagittal suture) in the 
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medial-lateral plane was identified, where a burrhole roughly 2 to 3 mm in diameter was 
drilled through the skull until the underlying dura was exposed, as described in figure 2.5  
The dura was then punctured with the tip of a 27 gauge syringe to expose the surface of 
the brain over the parietal cortex. 
  
Figure 2.5:  Retrograde labeling of left parietal transcallosal neurons.  A burrhole was made in the skull 
overlying the right parietal cortex at the specified coordinates, and the fluorescent retrograde dye was 
injected into the contralateral axon target site of the target neuronal population. 
 
 0.4 uL of a 4% solution of Fluorogold™ (FG), stored in a lightproof container, 
was drawn up using a glass micropipette, which was attached to the arm of the 
stereotactic frame.  The retrograde fluorescent dye was then delivered using the 
micropipette at the previously identified point, -0.8 mm caudal and 4.0 mm to the right 
relative to Bregma, into the neocortex at a depth of 2.5 mm below the pial surface.  This 
 30
depth was calculated to deliver the dye near the junction between cortical layers IV and 
V.  The dye was injected slowly over about 2 minutes at an average rate of about 0.005 
uL per second. 
 After the dye injection was complete, any obvious bleeding was stopped by the 
application of gentle pressure.  4.0 Silk suture was used to close the skin.  The surgical 
site was cleaned with sterile water, and inhalation anaesthesia was discontinued.  The 
animal was placed on a paper towel in a fresh cage and observed until it was awake and 
active.  We waited seven days prior to any additional surgical procedures to allow for 
sufficient labeling of the contralateral transcallosal neurons through retrograde transport 
of the FG. 
 
2.2.3  Preparation of the Osmotic Mini-pumps 
 We used Alzet Osmotic Mini-pumps with brain infusion kits (Model 2001, 
Durect, Cupertino, CA) for our experiments.  Solutions were prepared 24h prior to 
implantation.  All preparations were done under sterile conditions.  The attachment knob 
on each brain infusion cannula tip was glued to a cut piece from the base of a sterile 
standard medium sized pipette tip.  The length of the cannula tip was set to 3.0 mm, the 
shortest available length.  The cannula tips were then attached to the provided tubing, 
which were cut to 7.5 cm in length, and attached at the cut end to the mini-pump 
reservoir cap.  The cannula tip, tubing and reservoir cap, along with the reservoir, were 
weighed while empty.  The mini-pump reservoir and cannula tubing were then filled 
completely using the provided 1 mL syringe and blunt syringe tip and attached together, 
taking care to avoid bubble formation in the cannula tubing.  Mini-pumps were filled 
with test solution (9 ug/mL solution of anti-FGF-2 in PBS, 9 ug/mL rabbit serum IgG in 
PBS, or with the vehicle alone). 
 After filling, the mini-pump reservoir and attached brain infusion cannula were 
re-weighed once filled to ensure that the filled weight was at least 250 mg more than the 
empty weight.  The mini-pump reservoir and attached cannula were then placed in a 
sterile beaker and submersed in sterile phosphate buffered saline, and incubated at 37.0°C 
for 24 h. 
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2.2.4  Implantation of the Osmotic Mini-pumps 
 Experimental animals which had their left parietal transcallosal neurons labeled 7 
days prior were once again anaesthesized with halothane and placed in the stereotactic 
frame.  The skin over the top of the skull was shaved again, and the shave extended over 
the shoulders and back.  The whole area was prepped as before with isopropyl alcohol 
and the sterile field was set up as before. 
 The silk stitches closing the prior incision were cut with a pair of fine scissors and 
the previous incision in the midline of the scalp was reopened.  The incision was 
extended caudally 2.0 to 3.0 cm with a scalpel through the skin, and a subcutaneous 
pocket was created by blunt dissection using a pair of scissors.  The mini-pump reservoir 
was then placed inside the subcutaneous pocket. 
 The coronal and sagittal sutures and the Bregma point were re-exposed, with any 
scar tissue or blood clot from the prior surgery removed with blunt dissection.  Scar tissue 
and other debris was removed from the right sided burrhole where the FG had been 
imjected until the pial surface was once again visible.  Prior to placement of the mini-
pump brain cannula, the skull was thoroughly dried with a cotton swab. 
 A 3.0 mL syringe was attached to the stereotactic frame arm, and the cut piece of 
pipette tip base that had been glued to the mini-pump attachment knob was screwed 
firmly into Luer hub at syringe end.  The implantation of the mini-pump brain cannulae, 
described in figure 2.6, was performed with the aid of the operating microscope.  For 
contralateral mini-pump implantations, the mini-pump brain cannula was placed into the 
brain at the coordinates -0.8 mm to Bregma in the rostral-caudal plane and 4.0mm in the 
medial-lateral plane on the right side, through the same burrhole and in the same cortical 
location as the FG had been injected previously. 
 For ipsilateral minipump implantations, a second burrhole was made on the left 
side of the skull, at the coordinates -0.8 mm to Bregma in the rostral-caudal plane and 
4.0mm in the medial-lateral plane to the left side of midline.  The dura once exposed was 
opened once again with the tip of a 27 guage syringe needle and the underlying pia of the 
left parietal cortex was exposed.  The mini-pump brain cannula was then implanted at 
those same coordinates on the left side. 
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 After the brain cannulae were implanted into the brain, an acrylic glue was 
squirted liberally over the plastic cannula knob until its entire height was covered in glue.  
The glue was allowed to dry for 3 to 5 minutes until it was noticeably hardened.  After 
this, the brain cannula was detached from the stereotactic frame arm by cutting off the 
portion of the knob attached to the pipette tip end screwed into the syringe with a pair of 
fine scissors. 
  
 
Figure 2.6:  Implantation of osmotic minipumps at ipsilateral (left) and contralateral (right) sites.  The same 
burrhole made for retrograde dye injection was re-used for contralateral mini-pump implantation. 
 
 For bilateral mini-pump implantations, both mini-pump reservoirs were first 
placed side by side in the subcutaneous pocket in the animal’s back.  The ipsilateral mini-
pump cannula was implanted in the brain and glued into place first.  After detachment of 
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the ipsilateral brain cannula, the contralateral brain cannula was attached to the 
stereotactic frame arm via the 3.0 mL syringe and implanted as described above into the 
contralateral burrhole. 
 After the acrylic glue was dry and the brain cannulae were securely fixed in place, 
the scalp was closed over the midline and sutured with 4.0 Silk suture.  The animals were 
recovered from anaesthesia in the same manner as previously described for the injection 
of retrograde tracer dye. 
 
2.2.5  Stereotactic Callosotomy 
  
 
Figure 2.7:  Bony removal and cortical incision for stereotactic callosotomy.  A slit was drilled through the 
skull bone 1.2 mm lateral to the midline to accommodate a 4.0 mm cortical incision. 
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 The animals previously injected with FG were anaesthetized and positioned, and 
the surgical field prepared, as previously described.  The midline scalp incision was re-
opened after cutting the silk suture.  The top of the skull was exposed such that the 
coronal and sagittal sutures were visible and the Bregma point easily identified.  With the 
aid of the operative microscope, a slit was drilled through the skull 1.2 mm lateral to the 
midline defined by the sagittal suture on the right side spanning a length of 5 to 6 mm 
with the approximate center at -0.8 mm to Bregma in the rostral-caudal plane, as 
illustrated in figure 2.7.  The width of the slit was between 2.0 and 3.0 mm.  Care was 
taken not to injure the sagittal sinus, which was visible at the medial margin of the bony 
exposure. 
 The technique for the stereotactic callostomy is summarized in figure 2.8.  The 
callosotomy knife was prepared prior to the procedure.  It was made by bending 1.5 to 
2.0 mm of the tip of a 25 gauge syringe needle at an angle of 135° such that the cutting 
edges of the needle tip were oriented up and down when the needle tip was pointed 
forward.  The callosotomy knife was screwed onto a 3.0 mL syringe that was attached to 
the stereotactic frame arm. 
 After drilling the site in the skull bone, excess bone dust was removed with a 
cotton swab to expose the dura.  The stereotactic coordinates were set to -2.8 mm to 
Bregma in the rostral-caudal plane and 1.2 mm to Bregma in the medial-lateral plane to 
the right.  The callosotomy knife was lowered until the needle tip just touched the dura.  
The dura was then opened by carefully moving the callosotomy knife slightly up and 
down until the needle tip punctured the dura.  The needle tip was then advanced slowly 
by moving the stereotactic frame arm, and the dura split by moving the callosotomy knife 
up slightly.  This was repeated, gradually advancing the callosotomy knife forward until 
the dura was opened along the entire length of the bony exposure. 
 After the dura was opened, the needle tip callosotomy knife was repositioned in 
the rostral-caudal plane to -0.8 mm to Bregma.  The callosotomy knife was then lowered 
slowly to a depth of 4.0 mm, until it cut through the anterior portion of the body of corpus 
callosum and entered the underlying lateral ventricle.  A small gush was CSF was seen 
coming up out of the cortical incision at this point.  The callosotomy knife was then 
advanced rostrally in the rostral-caudal plane 2.0 mm, to +1.2 mm relative to Bregma, 
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and lowered to 5.0 mm of depth, cutting through the genu and rostrum of the corpus 
callosum.  The knife was then raised back to a depth of 4.0 mm and moved caudally 4.0 
mm, to -2.8 mm to Bregma, and slowly withdrawn to sever the fibres of the middle 
portion of the body of the corpus callosum.  Overall, the anterior third to one half of the 
corpus callosum was divided in this manner, sparing the posterior third overlying the 
hypothalamus and avoiding hypothalamic injury. 
 
Figure 2.8:   Stereotactic callosotomy technique.  A) The callosotomy knife was made by bending the tip of 
a 25 guage syringe needle with the cutting edges facing up and down.  B) The cortical incision was made 
1.2 mm lateral to midline on the right side and 4.0 mm in length.  C) The callosotomy knife was inserted at 
-0.8 mm to Bregma to a depth of 4.0 mm, advanced 2.0 mm, then lowered 1.0 mm more to cut the genu and 
rostrum, raised back to 4.0 mm, moved back 4.0 mm to cut the middle portion of the body of the corpus 
callosum, then withdrawn. 
 
 Bleeding from the cortical incision invariably occurred during insertion and after 
withdrawal of the callosotomy knife.  Excess blood was soaked up with strips of filter 
paper.  Gentle pressure was applied with bits of cotton or cotton swabs until the bleeding 
stopped.   
 For experiments that combined callosotomy with mini-pump implantation, the 
burrhole for the ipsilateral mini-pump cannula was drilled on the left side of the skull 
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prior to performing the callosotomy because drilling the callosotomy slit frequently 
obliterated or distorted the Bregma point used as a landmark for localizing the burrhole.  
The actual mini-pump implantation was performed after completion of the callosotomy. 
 Closure of the operative incision was performed in the same manner as previously 
described. 
 
2.2.6  Perfusion of Animals and Harvesting of Brain Tissue 
 Experimental animals were sacrificed 7 days after mini-pump implantation and/or 
callosotomy.  Animals were deeply anaesthetized with intraperitoneal injections of 0.3 
mL of Somnotol, and fixed in a supine position using tape.  A ventral midline incision 
was made from the throat to the abdomen.  The skin was retracted and a transverse 
incision was cut through the abdominal wall with a pair of fine scissors, opening the 
peritoneal cavity.  The diaphragm was cut and heavy scissors were used to cut the rib 
cage on both sides.  The base of the sternum was firmly grasped with a hemostat clamp 
and reflected upwards to expose the heart and lungs. 
 The heart was grasped with atraumatic forces, and a small incision was made with 
fine scissors in the inferior pole of the left ventricle.  A blunt cannula was inserted into 
the opened left ventricle until the tip was just within the ascending aorta, and clamped in 
place with a hemostat.  The animal was pre-flushed with 50 mL of cold 100 mM PBS 
administered through an automatic pump at a rate of 18 to 25 mL / min.  A small hole 
was cut in the right atrium as the flush began to relieve flow.  Then the animal was 
transcardially perfused with cold 4% paraformaldehyde (PFA) in 100 mM PBS until the 
liver paled and the carcass noticeably stiffened.  The volume of PFA used averaged 
between 200 to 250 mL per animal. 
 The surgical incision on the back of the skull was reopened and extended.  The 
temporalis muscle was cut free from its attachment on the skull on both sides.  A small 
rongeur was used to removed the C1 posterior arch and skull bone to expose the brain 
from cerebellum to the cerebral hemispheres up to the beginning of the olfactory bulbs.  
The spinal cord was cut at the C1 level.  A flat spatula was slipped underneath the brain 
to dissect free the cranial nerves, allowing the entire brain to be lifted from the skull base.  
The brain was then immersed in PFA and post-fixed overnight at 4°C. 
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2.3  HISTOLOGIC IDENTIFICATION OF TRANSCALLOSAL NEURONS 
 Coronal tissue blocks 3 to 5 mm in width spanning the infusion sites were 
sectioned from the post-fixed brains, cryoprotected by sinking in 10% sucrose for 4 to 8 
h, then 20% sucrose overnight on a rotator in a cold room (4°C), and embedded in OCT 
compound and frozen with dry ice.  Coronal sections were cut in a cryostat at 6 um 
through the injection sites and thawed onto ProbeOn Plus (FisherBiotech, Edmonton, 
Alberta, Canada) slides. 
 Each slide was mapped with fluorescent microscopy prior to further processing.  
Composite maps were assembled from individual low power micrographs of these areas 
using Adobe Photoshop™ image processing software. 
 
2.4  IN SITU HYBRIDIZATION 
 In-situ hybridization was validated using control hybridization solutions that 
included no labeled probe, or labeled GAP-43 probe and 1000X excess unlabeled GAP-
43 probe.  Both procedures resulted in a hybridization signal no higher than background.  
When hybridization was performed with labeled GAP-43 probe combined with 1000X 
excess unlabeled oligonucleotide complimentary for Tα1-tubulin or c-Jun mRNA, the 
GAP-43 mRNA hybridization signal was not diminished. 
 The oligonucleotide probe for GAP-43 mRNA and hybridization cocktail solution 
we used were available and previously used in our laboratory.(Karimi-Abdolrezaee and 
Schreyer, 2002)  The probe was labeled with 35S at the 3’ end one day prior to use.  The 
following reagents were mixed in a sterile 1.5 mL Eppendorf tube: 
 2.5 µL 5X reaction buffer (Amersham, provided with terminal transferase) 
 8.0 µL autoclaved triple-distilled water 
 2.0 µL oligonucleotide probe (20 ng/mL) 
 10.0 µL of [35S]dATP (Dupont NEN, #NEG-034H) 
 3.0 µL terminal transferase (Amersham #T2230Z) 
 Gentle pipette mixing was performed after adding each ingredient except for the 
enzyme.  Because the enzyme tended to be very sensitive, it was kept in a freezer 
container until use, and added quickly without mixing.  The mixture was incubated in a 
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water bath at 37°C for 2.0 h.  In order to increase the efficiency of labeling, the first 2.0 
µL of terminal transferase was added initially, and the remaining 1.0 µL added after 1.5 h 
of incubation. 
 The reaction was stopped by adding 20 µL of tris-HCl and purified using a 
Chroma Spin-10 column (Clontech).  The Chroma Spin columns were prepared as per 
manufacturer instructions.  They were first inverted to suspend the gel matrix, opened, 
and placed in 2 mL microcentrifuge collection tubes, and centrifuged at 1800 rpm (700G) 
for 5 minutes.  The columns were then placed in fresh microcentrifuge tubes, and the 
labeled probe reaction mixture was added by drop pipetting it into the center of the gel 
bed.  5 µL of salmon sperm DNA was added as well.  The columns were centrifuged 
again at 1800 rpm for 5 minutes, and the purified labeled probe was collected afterwards 
from the bottom of the microcentrifuge tube.  A 2 µL sample was withdrawn and the 
amount of radioactivity was measured by liquid scintillation. 
 Pretreatment of experimental slides were performed one day after labeling of the 
oligonucleotide probe was complete, using the following procedure. 
 1. Slides were removed from the freezer and air dried for 15 minutes 
 2. Slides were fixed in 4% PFA for 15 minutes 
 3. Slides were washed 3 X 5 minutes in 10 mM PBS. 
4. While the slides were soaking in the PBS, a 20 ug/mL solution of proteinase K 
was prepared. 
5. Slides were treated with the proteinase K for 6 minutes. 
6. Slides were post-fixed for 5 minutes in 4% PFA. 
7. Slides were rinsed 2 X 5 minutes in 10 mM PBS. 
8. Slides were rinsed in DEPC-H2O for 5 minutes. 
9. Slides were dehydrated in alcohol: 
 1 minute in 70% EtOH. 
 1 minute in 90% EtOH. 
 30 seconds in 100% EtOH. 
 After pretreatment was completed, the slides were left to air dry in a dark place 
for 30 minutes.  Previously frozen hybridization cocktail was thawed in a 43°C water 
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bath.  100 mL of hybridization solution was prepared for each slide to be hybridized was 
made using the following recipe. 
 For each 1 mL, vortexing after adding each component: 
 900 µL hybridization cocktail. 
100 µL salmon sperm DNA (10 mg/mL boiled for 5 minutes, then chilled for 5 
minutes immediately before use.) 
107 cpm 35S-labelled probe. 
40 µL 5 M DTT 
 Hybridization boxes were prepared by lining the bottom with filter paper strips 
and moistening with triple-distilled water.  180 uL of hybridization solution was then 
applied to the surface of half of the experimental slides.  On top of each of these slides a 
second experimental slide was placed using a hinge technique, taking care to avoid 
trapping air bubbles.  The hybridization box was taped firmly closed and placed in an 
oven at 43°C for 14 to 18 hours. 
 While the hybridization reaction is incubating overnight, 2 to 3 L of 1X SSC was 
warmed in a 55°C water bath.  After the hybridization reaction was complete, two rinsing 
dishes and two 250 mL beakers were filled with warm 1X SSC.  A slide rack was placed 
in one of the rinsing dishes.   The hybridization box was removed from the incubating 
oven and opened.  Each pair of slides was transferred to one 250 mL beaker and gently 
separated.  One slide was placed in the second beaker while the other slide was placed in 
the slide rack.  Then the first slide was transferred to the slide rack, taking care to keep 
the slides immersed in 1X SSC at all times.  When the rack was filled, it was transferred 
to the second rinsing dish and rinsed for one minute.  The slides were then rinsed 4 x 15 
minutes in 1X SSC at 55°C in the water bath.  The last rinsing dish was then removed 
from the water bath and allowed to cool for 15 to 30 minutes. 
 The slides were then dipped 1 second each in 2 dishes of distilled water, 6 X 1 
second in 60% EtOH, and 12 x 1 second in 95% EtOH, then left to dry in a dust-free, 
dark environment. 
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2.5  QUANTIFICATION OF GAP-43 mRNA EXPRESSION 
 After in-situ hybridization, slides were developed by dipping in NTB2 nuclear 
track emulsion (Eastman Kodak, Rochester, NY).  To prepare the emulsion, 12 to 15 mL 
of emulsion cream was added to an equal volume of distilled water in a dark room and 
melted in a warm water bath for 30 minutes.  Slides were dipped back to back, with tissue 
side facing outwards, and dried on a rack for 3 hours.  The dipped slides were transferred 
to slide boxes in the dark, and each box was wrapped in light proof dark plastic bags, 
which were left to expose at 4°C.  Test slides were developed at one week intervals to 
determine when the experimental slides were ready for development.  Total exposure 
time for experimental slides ranged from 8 to 28 days.  Emulsion coated slides were 
developed in D19 (Eastman Kodak) for 3 min and fixed in undiluted Rapid Fix (Kodak) 
for 5 min.   
 A Zeiss Axioskope microscope set with dark field optics was used to assess the 
pattern of cell labeling with the GAP-43 mRNA probe.  Sections were counterstained 
with cresyl violet for visualization of silver grains with bright field illumination.  Low 
power bright field composite maps were assembled, as shown in figure 2.11, and the 
transcallosal neurons were identified by overlaying the fluorescent map of the same 
section over the bright field map using Adobe Photoshop™ image processing software. 
 High power images over each identified TCN were captured using bright field 
optics, and a Northern Eclipse™ subroutine was used to quantify silver grain density 
within the fluorescently labeled cells.  Background silver grain density was determined as 
the average silver grain density of at least five high power images over cell free areas of 
the molecular zone overlying the area of analysis.  GAP-43 mRNA expression of 
individual TCNs was calculated by dividing the value returned by the Northern Eclipse™ 
subroutine for each individual neuron by the average background value. 
 41
 
 
 
 
RESULTS AND ANALYSIS 
 
3.0  DETERMINATION OF ANTIBODY ACTIVITY AND SPECIFICITY 
 
3.0.1  Western Blot 
 
  
Figure 3.1:  Western blot of purified recombinant FGF-2 and rat cortex extract demonstrated specificity of 
test antibody to FGF-2, and the presence of FGF-2 in adult rat cortex. 
 
 To document the specificity of the antibody used to block FGF-2 in the cerebral 
cortex we determined that the anti-FGF-2 was capable of specifically detecting both 
purified recombinant human FGF-2, and FGF-2 in tissue extracts of rat cortex.  A single 
band of 17 kDa size was observed in western blots of rat cortex extract, while blots of 
purified human recombinant FGF-2 detected a primary band of approximately 15 kDa in 
size, and a faint secondary band of 17 kDa in size.  The observed difference may be 
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attributed to different degrees of heparin complex formation between the two test 
samples, as well as possible differences in the properties of human and rat FGF-2.  The 
results of the western blot are shown in figure 3.1 
 
3.0.2  Cell Proliferation Assay 
 We verified that the anti-FGF-2 antibody purchased from Sigma™ possessed 
function blocking activity as claimed by the manufacturer.  Our method was to determine 
if the antibody would block the ability of exogenous FGF-2 to stimulate the proliferation 
of cultured 3T3 fibroblasts. 
 
Figure 3.2:  Results of a cell proliferation assay of 3T3 fibrobasts grown in the presence of varying 
concentrations of FGF-2 and anti-FGF-2.  A) Increasing concentrations of FGF-2 result in logarithmically 
higher rates of cell proliferation.  B) The presence of 20 ug/mL of anti-FGF-2 substantially inhibits the 
activity of FGF-2. 
 
 The results of the cell proliferation assay are shown in figure 3.1.  The rate of cell 
proliferation of 3T3 fibroblasts grown in DMEM culture medium with 0.5% horse serum 
initially increased with increasing concentrations of FGF-2, then reached a plateau and 
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began to fall as concentrations of FGF-2 continued to increase.  This finding was 
consistent with previously reported observations.(Davies et al., 1997a) 
 The addition of 20 ug/mL of anti-FGF-2 to the culture medium substantially 
inhibited the proliferation of 3T3 fibroblasts grown in medium containing 0 to 5 ng/mL 
of FGF-2.  Percent inhibition was calculated using the formula % inhibition = (Signal 
Intensityexperimental antiFGF-2 concentration – Signal Intensityno antiFGF-2) / (Signal Intensityno antiFGF-2 
– 1).  20 ug/mL of anti-FGF-2 inhibited 69.4 +/- 11.3 % of the activity of  0.04 ng/mL of 
FGF-2, 65.6 +/- 8.1% of the activity of 0.2 ng/mL FGF-2, 76.7 +/- 8.2% of the activity of 
1.0 ng/mL FGF-2, and 56.3 +/- 18.1% of the activity of the activity of 5.0 ng/mL FGF-2.  
A percent inhibition of 65.7 +/- 3.6% was also observed even when no FGF-2 was added 
to the culture medium, and is most likely attributed to the inhibition of the activity of low 
levels of endogenous FGF-2 present in horse serum, or produced by cells in culture. 
 
 
3.1  QUALITATIVE OBSERVATIONS 
 Observations of brain sections under fluorescent microscopy prior to in situ 
hybridization revealed variable intensity of FG labeling of TCNs between individual 
animals.  Some animals exhibited extremely strong fluorescent labeling where a large 
number of pyramidal neurons in the parietal cortex took up the fluorescent dye after a 
contralateral injection of FG, while other animals only had a few fluorescently labeled 
neurons.  In all experimental animals, the homologous nature of the transcallosal 
projection was confirmed by the observation of abundant fluorescently labeled pyramidal 
neurons in ipsilateral parietal cortical areas homologous to the contralateral FG injection 
site.  Other areas of fluorescent labeling were also observed in some sections, including 
far lateral cortical areas, and medial cingulate cortex.  These distant areas were not 
analyzed in our experiments. 
 An example of a composite fluorescent map of the area of analysis around an 
ipsilateral mini-pump infusion site is shown in figure 3.3.  In all experimental animals, 
the laminar distribution of labeled neurons in layers II/III and V was readily apparent on 
fluorescent microscopy.  The injection site scar was easily identifiable on most sections. 
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Figure 3.3:  Composite fluorescent map of left parietal cortex area homologous to the contralateral FG 
injection site.  Labeled TCNs are found predominantly in layers II/III and V.  The yellow oval marks the 
area of scar around the ipsilateral infusion site. 
 
  
 
Figure 3.4:  Left parietal cortex around an infusion site scar.  Low power (10X) bright field composity map. 
Cresyl violet stain. 
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 The overall intensity of fluorescent labeling remained more or less consistent for 
extended distances rostral and caudal to the FG injection site.  The rostral-caudal distance 
between the first and last analyzed sections varied from animal to animal from 108 to 444 
nm, and no quantitative differences were observed in the overall intensity of FG labeling 
between sections taken from any single animal regardless of the distance of that section 
from the FG injection site. 
 Some variability was also seen in the extent of the tissue damage associated with 
the mini-pump cannula implantation.  In the majority of animals the entirety of the scar 
area could be seen encompassed within about half of a single low power (10X) field on 
light microscopy, the obvious scar could be seen on sequential sections through distances 
ranging from 100 to 200 nm apart.  In most animals, some subtle evidence of tissue 
damage could usually be seen in all analyzed sections regardless of distance from 
implantation site.  An example of a typical mini-pump cannula scar site is shown in 
figure 3.4. 
 Bright field microscopy also confirmed placement of mini-pump cannula into 
parietal cortex in all animals, as the distinct cytoarchitecture of parietal cortex with a 
thick, well defined granular layer IV was seen lateral to the cannula scar site in all 
animals, and medial to the scar site in most animals.  Motor cortex could be identified 
histologically in some sections of some animals by the disappearance of an obvious 
granular layer IV in cortical areas some distance medial to the cannula scar site. 
 The completeness of the callosotomy was confirmed by histological examination 
under very low power (4X) bright field microscopy, showing a callosotomy scar 
transecting the entire thickness of the corpus callosum.  The degree of tissue damage 
associated with the callosotomy scar ranged from mild to moderate.  In two animals, 
attempted callosotomy failed to transect the corpus callosum at any point along the 
rostro-caudal extent of examined sections.  In these animals the scar from the midline 
incision could be seen reaching the superior edge of the corpus callosum but not 
continuing further downwards to cut through the callosal fibers.  These animals were 
subsequently analyzed as a separate sub-group.  An example of the scar from a successful 
callosotomy is shown in figure 3.5. 
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Figure 3.5:  Callosotomy scar. Composite low-power (4X) micrographs. (Left panel) Callosotomy through 
the entirety of the corpus callosum into the underlying lateral ventricle. (Right panel) Comparison to a 
pristine corpus callosum. 
 
 High power composite micrographs of representative sections of experimental 
subgroups after in-situ hybridization are shown in figure 3.6.  Qualitative differences can 
readily be seen between experimental groups.  High densities of silver grains, 
representing elevated expression of GAP-43 mRNA, can be seen in the two experimental 
subgroups that had bilateral blockades of FGF-2 signaling: the bilateral antibody infusion 
subgroup (B) and the callosotomy with ipsilateral antibody infusion subgroup (E).  In 
contrast, the control (A), ipsilateral antibody infusion (C), contralateral antibody infusion 
(D), and callosotomy with ipsilateral saline vehicle subgroups, which had either unilateral 
or no blockade of FGF-2 signaling, had lower densities of silver grains.   
 Interestingly, when fluorescent maps are overlaid on top of bright field images of 
the same area to identifiy transcallosal neurons, neurons not labeled by FG were also seen 
to have high densities of silver grain labeling.  The numbers of such neurons were clearly 
highest in the two groups with bilateral FGF-2 signal blockade, but the occasional highly 
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labeled neuron could be seen in the unilateral FGF-2 blockade and control groups as well.  
These groups also had a few rare fluorescently labeled neurons exhibited high silver grain 
density, but the majority of observed neurons in these groups, both fluorescently labeled 
and not labeled, displayed only low silver grain density.  In contrast, many neurons, 
regardless of fluorescent labeling, exhibited high silver grain density in the two bilateral 
FGF-2 signal blockade subgroups. 
 
Figure 3.6:  Representative composite micrographs of experimental groups.  Overlay of fluorescent maps 
over bright field images identifies TCNs.  Density of silver grains reveals GAP-43 mRNA expression 
within individual labeled cells.  A) Control group (bilateral PBS).  B) Bilateral antiFGF-2.  C) Ipsilateral 
antiFGF-2.  D) Contralateral antiFGF-2.  E) Callosotomy with ipsilateral antiFGF-2.  F) Callosotomy with 
ipsilateral PBS. 
 
 We chose not to investigate these non-fluorescently labeled neurons that appeared 
to up-regulate GAP-43 mRNA expression in this experimental project due to time and 
resource constraints.  The identities and properties of these neurons is a potential area for 
fruitful future investigations. 
 
3.2  SUMMARY OF RESULTS:  MEAN LEVELS OF GAP-43 mRNA EXPRESSION 
 
 For those neurons that were successfully fluorescently labeled and thus identified 
as TCNs, the density of silver grain labeling was quantified for individual neurons.  The 
mean levels of GAP-43 mRNA expression for all the labeled TCNs in each experimental 
sub-group were then calculated and are given in Table 3.1.   
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Table 3.1:  Summary of Experimental Groups and Results 
Experimental Group    N n GAP-43 mRNA Expression 
        Mean ± Std Err   
Control Groups 
     No intervention (FG only)   3  682 6.591 ± 1.160 
     Bilateral Saline Vehicle (PBS)  3  931 5.725 ± 0.314 
     Bilateral rabbit serum IgG*  3  801 6.466 ± 0.363 
    
     Pooled Control    9 2414 6.261 ± 0.387  
   
 p-value** 
Experimental Group 1 
     Bilateral antiFGF-2***   5 2388 11.586 ± 0.449  0.000006   
     Ipsilateral antiFGF-2   3  740 7.558 ± 0.963    0.309 
     Contralateral antiFGF-2   3 1471 7.736 ± 0.607    0.113 
Experimental Group 2 
     Callosotomy + antiFGF-2   4 1645 12.723 ± 0.385  0.000001 
     Callosotomy + PBS   3 1250 6.782 ± 0.714    0.563 
     Incomplete Callosotomy + antiFGF-2 2  550 7.602 ± 0.109    0.021 
N = number of animals in a group,  
n  = number of neurons analyzed in a group 
* The concentration of rabbit serum IgG used was 9.0 ug/mL 
** p-values calculated versus Pooled Control 
*** The concentration of anti-FGF-2 for all experimental sub-groups using antiFGF-2 was 9.0 ug/mL 
    
3.2.1  Control Group 
 Three separate experiments were designed to act as controls.  In the first 
experiment, naïve animals treated only with FG injection to identify TCNs were analyzed 
to determine the baseline level of GAP-43 expression in adult rat parietal cortex.  To 
ensure that nonspecific effects secondary to saline vehicle and/or cortical injury from 
mini-pump implantation itself would be accounted for, a second control experiment was 
performed with animals treated with bilateral infusions of saline vehicle alone (10 mM 
PBS).  To determine what effects, if any, might be caused by non-specific effects of 
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immunoglobulins, a third control experiment was done using bilateral infusions of 9.0 
ug/mL rat serum IgG. 
 Using a threshold value of 5 times background for labeled versus unlabeled 
neurons, the TCNs of each experimental animal were divided into four subpopulations 
based on their level of GAP-43 mRNA expression:  no GAP-43 expression (<5 X 
background), low GAP-43 expression (5 to 10 X background), moderate GAP-43 mRNA 
expression (10 to 15 X background), and high GAP-43 mRNA expression (>15 X 
background).  The mean proportions of neurons found in each subpopulation are plotted 
in figure 3.4 for each of the three control experimental groups for comparison. 
  
 
Figure 3.7:  Proportion of neurons in control experiments with varying levels of GAP-43 mRNA 
expression.  (Inset) Mean levels of GAP-43 mRNA expression in control experiments. 
  
 ANOVA analysis of the three control experimental sub-groups showed no 
significant differences between them for either mean GAP-43 mRNA expression levels 
(F = 0.417, p = 0.677) or the proportion of cells with high levels of GAP-43 mRNA 
expression. (F = 0.200, p = 0.824)  Therefore, these results were combined together to 
 50
produce a single pooled group that was used as a control for comparison with all 
subsequent experimental sub-groups. 
 
3.2.2  Experimental Group 1:  Bilateral and Unilateral FGF-2 Blockade 
 In experimental group 1 we examined the levels of GAP-43 mRNA expression 
produced after 7 days of bilateral FGF-2 blockade using 9 ug/mL of anti-FGF-2 infused 
through osmotic mini-pumps.  We hoped to block FGF-2 signaling from the majority of 
both local (ipsilateral) and distal (contralateral) axon target sites using this method, and 
therefore remove any retrograde repression that FGF-2 might be providing for the 
transcallosal neurons.  We then compared the levels of GAP-43 mRNA expression 
obtained after bilateral FGF-2 blockade with that obtained after incomplete unilateral 
FGF-2 blockades.   
 
Figure 3.8:  Results for experimental group 1, comparing bilateral, ipsilateral, and contralateral antibody 
infusion sub-groups with the pooled control group.  GAP-43 mRNA levels for each individual TCN 
plotted, with mean values represented by overlaid bars.  Error bars represent one standard error in either 
direction. 
 
 Theoretically, an ipsilateral anti-FGF-2 infusion should block FGF-2 signaling 
from local axon target sites, but not affect any signaling coming from the distal axon 
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target sites in the contralateral hemisphere.  Similarly, a contralateral anti-FGF-2 infusion 
should block FGF-2 signaling from the distal axon target sites, but spare any signals 
provided by local axon target sites in the ipsilateral cortex. 
 The results for experimental group 1 are summarized in figure 3.8.  Values for 
individual neurons are plotted as points while the mean level of GAP-43 mRNA 
expression calculated for controls and experimental group 1 are represented by the 
overlaid bar graph (numerical values given in table 3.1).  Comparisons between 
individual sub-groups were conducted using Student’s t-test.  When the action of FGF-2 
was blocked bilaterally at both local and distal axon target sites, the mean GAP-43 
mRNA expression per TCN was significantly elevated when individually compared to 
the pooled control group value (p = 0.000006),  the ipsilateral antibody infusion subgroup 
(p = 0.034), and the contralateral antibody infusion subgroup (p = 0.006).  ANOVA 
analysis of the bilateral, ipsilateral and contralateral subgroups together also showed a 
significant difference between them (F = 14.35, p = 0.002). In contrast, the mean GAP-43 
mRNA expression per TCN observed in animals that received ipsilateral or contralateral 
antibody infusions where not significantly different from the pooled control, (p = 0.309 
and p = 0.113 respectively) or each other. (p = 0.88)  Thus bilateral FGF-2 blockade 
resulted in an increase of GAP-43 expression in TCNs while unilateral blockades in 
isolation, both ipsilateral and contralateral, had no significant effect.   
 
3.2.3  Experimental Group 2:  Callosotomy With and Without Local FGF-2 Blockade 
 Having found that a bilateral blockade of FGF-2 signaling appeared to result in an 
up-regulation of GAP-43 expression, we next wanted to investigate the regulation of 
GAP-43 expression after axonal injury in transcallosal neurons.  Since all contralateral 
target signals to TCNs should in theory be interrupted by callosotomy, the bilateral 
infusion results suggested that a local ipsilateral blockade of FGF-2 signaling should 
result in an up-regulation of GAP-43 mRNA expression when combined with 
callosotomy.  Therefore, in experimental group 2, we investigated the effect of 
stereotactic callosotomy (see figure 3.5) on the expression of GAP-43 in transcallosal 
neurons 7 days post axotomy, with or without a simultaneous blockage of local FGF-2 
signaling by ipsilateral antibody infusion via an osmotic mini-pump.   
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 The results for this experimental group are summarized in figure 3.9 (numerical 
values given in table 3.1).  Callosotomized animals treated with simultaneous ipsilateral 
antibody infusion had mean levels of GAP-43 mRNA significantly higher than the 
control group. (p=0.000001)  On the other hand, callosotomized animals that received 
ipsilateral infusions of only saline vehicle had a mean GAP-43 mRNA level which was 
not significantly different from the control group. (p = 0.563) 
 
 
Figure 3.9:  Results for experimental group 2, comparing callosotomy with ipsilateral antibody infusion and 
callosotomy without antibody infusion sub-groups with the control group.  Mean GAP-43 mRNA levels 
represented by bars overlaid on top of dot plots on each individual neuron.  Error bars represent one 
standard error in either direction. 
 
 In the two animals where the callosotomy procedure had failed, and the corpus 
callosum was not completely transected,  the GAP-43 mRNA levels were substantially 
lower than the levels observed in the completely callosotomized subgroup, similar to the 
levels observed in the ipsilateral and contralateral antibody infusion subgroups in 
experimental group 1, and not much higher than that seen in the fully callosotomized 
animals that did not receive the antibody infusion.  When compared with the pooled 
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control group, the small increase in GAP-43 expression reached significance (p = 0.021), 
but given an n of only 2, this calculation is inconclusive. 
 
3.2.4  Between Group Comparisons 
 Comparing experimental groups 1 and 2 together, no significant differences in 
GAP-43 expression were seen between the bilateral antibody infusion group and the 
callosotomy with ipsilateral antibody infusion. (p = 0.16)  ANOVA analysis of all six 
sub-groups together indicated significant difference. (p < 0.0001)  ANOVA analysis of 
the control group, both unilateral infusion groups, and the callosotomy group without 
antibody infusion showed no significant differences between these groups when analyzed 
together. (p = 0.27) 
 These results show that a bilateral blockade of FGF-2 signaling is sufficient to 
cause up-regulation of mean levels GAP-43 mRNA in transcallosal neurons.  We found 
no significant difference regardless of how the blockade was actually achieved, either by 
blocking FGF-2 biochemically at the location of axon target sites, or physically 
interrupting the axon tracts.  We also did not see any significant elevation of GAP-43 
expression resulting from any experimental manipulation that resulted in only a partial 
blockade of either the ipsilateral or the contralateral axon targets of TCNs. 
 
 
3.3  SUBPOPULATION ANALYSIS 
 
3.3.1  Neuron Subpopulations with Different Levels of GAP-43 Expression 
 A wide range of levels of GAP-43 mRNA was observed in individual TCNs, as 
demonstrated by the wide scatter in individual plot points seen in figures 3.8 and 3.9, in 
all experimental subgroups.  Regardless of the experimental manipulation, in any given 
animal, transcallosal neurons were found to exhibit levels of GAP-43 expression that 
varied from low to high.  While the number of neurons with high levels of GAP-43 
expression was clearly greater in the bilateral antibody infusion and the callosotomy with 
antibody infusion groups compared to the others, both these sub-groups nevertheless still 
had many neurons that remained with lower levels of GAP-43 expression.  Conversely, 
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even in the control group, a few neurons with higher levels of GAP-43 expression were 
observed.   
 Individual neurons were arbitrarily sorted into subpopulations with no, low, 
medium, and high levels of GAP-43 mRNA expression for the subgroups in experimental 
groups 1 and 2 in the same way as with the three control subgroups, as described in 
section 3.1.1, and compared with the pooled control group.  This is illustrated in figure 
3.10.  The numerical values for the percentage of neurons in each of the subpopulations 
with varying levels of GAP-43 expression are shown in table 3.2.  Large subpopulations 
of TCNs with medium and high levels of GAP-43 mRNA were seen only in the bilateral 
antibody infusion and the callosotomy with antibody infusion sub-groups.   
 
Figure 3.10:  Proportions of neurons with varying levels of GAP-43 expression in each experimental sub-
group. 
 
 Statistical analysis of subpopulation proportions confirmed the results found with 
whole population mean levels of GAP-43 mRNA.  The proportion of neurons with high 
levels of GAP-43 expression were significantly higher in both the bilateral antibody 
infusion and callosotomy with antibody infusion sub-groups when compared with the 
pooled control group (p = 0.0005 and p = 0.003, respectively) and not significantly 
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different from each other. (p = 0.15)  ANOVA analysis once again showed that each of 
these two sub-groups were significantly higher than all the others. 
 
Table 3.2:  Proportion of neurons with low, moderate, and high levels of GAP-43 
Expression in the Experimental Sub-Groups 
Experimental Group    Percentage of neurons per subpopulation 
      (± Standard Error) 
 None Low Moderate High 
 (<5X) (5-10X) (10-15X) (>15X) 
Pooled Control 44 ± 5.0 41 ± 3.4 12 ± 1.6 3.2 ± 1.1 
Experimental Group 1 
     Bilateral antiFGF-2* 12 ± 2.2 37 ± 2.5 27 ± 1.7 25 ± 2.7 
     Ipsilateral antiFGF-2 33 ± 9.8 45 ± 4.8 14 ± 2.9 8.3 ± 2.8 
     Contralateral antiFGF-2 35 ± 6.3 38 ± 2.9 17 ± 2.3 9.1 ± 1.5 
Experimental Group 2 
     Callosotomy + antiFGF-2 14 ± 1.2 30 ± 2.2 23 ± 1.3 32 ± 2.3 
     Callosotomy + PBS 41 ± 7.5 39 ± 1.5 16 ± 5.1 4.0 ± 1.0 
* The concentration of antiFGF-2 for all experimental sub-groups using antiFGF-2 was 9.0 ug/mL 
 
 Similarly, the bilateral antibody and callosotomy with ipsilateral antibody sub-
groups also had a significantly lower proportion of neurons no GAP-43 mRNA 
expression (p = 0.0001 and p = 0.0002 respectively) and not significantly different from 
each other (p = 0.65). 
 Visual inspection of the dot plots in figures 3.8 and 3.9 did not reveal any obvious 
clustering of neurons into groups with high or low levels of GAP-43 expression.  In order 
to determine whether or not there was discreet clustering of GAP-43 expression in 
individual TCNs into distinct ranges of values, the individual neurons in each 
experimental subgroup were pooled and sorted into 1 unit wide bins in order to construct 
population histograms, which are shown in figures 3.11 and 3.12.   
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Figure 3.11:  Population histograms for experimental group 1, showing proportions of cells with varying 
levels of GAP-43 mRNA expression compared with the control group. 
 
 
Figure 3.12:  Population histograms for experimental group 2, showing proportions of cells with varying 
levels of GAP-43 expression compared with the control group. 
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 An apparent unimodal distribution of GAP-43 expression in all experimental sub-
groups is seen, without distinct peaks.  The distribution of neurons is shifted rightward in 
the bilateral antibody infusion and the callosotomy with ipsilateral antibody subgroups, 
with greater proportions of neurons expressing higher levels of GAP-43 mRNA.   
 
  
3.3.2  Correlations of GAP-43 Expression with Cross-sectional Neuron Area 
 Because transcallosal neurons are generally of similar size and shape, the cross-
sectional area of any given neuron in a particular section would relate to the plane of 
transection through that particular neuron.  Comparisons of GAP-43 expression between 
sectioned neurons may be confounded if the distribution of GAP-43 mRNA in TCNs 
were uneven.  For example, if GAP-43 mRNA in TCNs clustered predominantly at the 
poles of the cell, then neurons with smaller cross-sectional areas may have preferentially 
higher levels of measured GAP-43 expression compared to neurons with larger cross-
sectional areas, since cross sections through the center of a pyramidal neuron would tend 
to be larger than cross sections through a pole. 
 To ensure that the measurements of GAP-43 expression in TCNs was not affected 
by this possibility, the neuronal cross-sectional area of each analyzed TCN was obtained 
using a Northern Eclipse subroutine, and correlated with observed levels of elevated 
GAP-43 expression in the bilateral antibody infusion and the callosotomy with antibody 
infusion sub-groups.  The mean neuron cross-sectional area was calculated for each of the 
no label, low, moderate, and high levels of GAP-43 mRNA expression subpopulations, 
and compared.  These results are given in table 3.3.  No differences were found in the 
mean neuron cross sectional area between any of the subpopulations with differing levels 
of GAP-43 expression.   
 The absence of differences in cross sectional areas between neurons with differing 
levels of GAP-43 expression also suggests that there were no major sampling differences 
between different sections taken from different animals, and that the experimental 
procedures did not differentially cause atrophy or hypertrophy in TCNs. 
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Table 3.3:  Mean size and distance to injection site for neurons expressing no, low, 
moderate, and high levels of GAP-43 mRNA 
Experimental Sub-Group   Neuronal Subpopulation 
 Unlabeled Low Moderate High 
 (<5X) (5-10X) (10-15X) (>15X) 
Cell Cross Sectional Area (nm2) 
     Bilateral antiFGF-2* 133.9 ± 8.2 135.0 ± 7.3 134.9 ± 5.1 133.7 ± 10.6 
     Callosotomy + anti-FGF-2 135.5 ± 5.6 135.5 ± 10.1 137.5 ± 11.8 142.9 ± 16.0 
Distance to injection site (µm) 
     Bilateral antiFGF-2 136.1 ± 5.4 139.4 ± 9.0 136.4 ± 12.8 135.6 ± 12.2 
     Callosotomy + antiFGF-2 124.6 ± 30.5 140.8 ± 22.3 137.9 ± 19.0 130.2 ± 15.7 
* the concentration of antiFGF-2 for all experimental sub-groups using antiFGF-2 was 9.0 ug/mL 
 
  
3.3.3  Correlations of GAP-43 mRNA Expression with the Distance of the Cell Body to 
the Injection Site 
 
 One potential explanation for the distribution of varying levels of GAP-43 
expression observed is that it was a result of a concentration gradient of the antibody 
diffusing out from the ipsilateral mini-pump infusion site.  If this were indeed true, it 
would be expected that neurons situated closer to the injection site should, on average, 
have higher levels of GAP-43 mRNA expression than neurons further away. 
 In order to investigate this possibility, the center of the injection site was 
determine to be located on the section that was exact halfway between the first section 
where the injection site scar became visible and the last section on which the scar was 
visible.  The distance of each analyzed section from the injection site section was 
calculated based on the number of cuts separating the two sections and the width of each 
individual section.  On each analyzed section, the distance of each labeled transcallosal 
neuron to the injection site scar was directly measured.  The actual distance between the 
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neuron and the center of the injection site was thus calculated using the following 
formula: 
  D = SQRT (da2+db2)  
  Where: 
  D = distance between neuron and center of injection site 
da2 = measured distance between neuron and injection site scar on tissue 
section 
db2 = calculated distance between tissue section and section with center of 
injection site 
 The mean distances for each of the unlabeled, low, moderate, and high GAP-43 
expression subpopulations were calculated for the bilateral antibody infusion and 
callosotomy with antibody infusion sub-groups, and given in table 3.3.  Once again, no 
discernable differences were observed between neurons far away and closer to the 
injection site. 
  
3.3.4  Levels of GAP-43 Expression in Medial versus Lateral Neurons 
 If the antibody diffused widely throughout the brain, then the possibility also 
exists that the antibody may have diffused across the midline, and both the ipsilateral and 
contralateral axon terminals of some transcallosal neurons may have been affected by 
antibody originating from a single site.  If this did happen, the effect should be most 
marked in the bilateral infusion experimental sub-group, where antibody diffusing across 
the midline from both sides would have created a zone of additively high concentration of 
diffusing antibody medial to the infusion sites.  One might then expect that neurons 
whose cell bodies were situated relatively medial might have higher levels of GAP-43 
expression, with their distal axon collaterals projecting to the homologous area of medial 
contralateral cortex. 
 Also, in the animals used in these experiments, primary motor cortex lay medial 
to the infusion site, while somatosensory cortex lay lateral.  While most of the neurons 
analyzed were clearly within sensory cortex, some of the most medial neurons may have 
been in motor cortex, and potential differences in GAP-43 expression between TCNs in 
sensory and motor cortex may have had an effect. 
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 The mean levels of GAP-43 expression found in transcallosal neurons with cell 
bodies medial to or lateral to the ipsilateral infusion site scar were compared for the 
bilateral antibody infusion and the callosotomy with contralateral infusion subgroups.  In 
the bilateral antibody infusion sub-group, the mean GAP-43 expression in medial neurons 
was 12.26 +/- 0.79, compared to 10.05 +/- 0.62 for lateral neurons (p = 0.09).  While not 
statistically significant, a trend towards medial neurons having higher GAP-43 expression 
levels in response to bilateral FGF-2 blockade is observed. 
 In the callosotomy with antibody infusion group, it would not be expected to 
observe any medial to lateral variation in GAP-43 expression, because the callosotomy 
would theoretically obliterate all signals originating from the contralateral side, such that 
the presence of contralateral antibody should not matter.  No significant differences were 
observed in this experimental sub-group between medial and lateral neurons, irrespective 
of their laminar location, (13.01 +/- 0.86 and 11.95 +/- 0.93, p = 0.28 respectively)  but 
the trend towards medial neurons having higher GAP-43 expression levels still remains, 
although it is statistically less strong.  These results suggest the possibility of a small 
effect from overlapping diffusion crossing the midline from the two bilateral infusion 
sites, combined with the presence of a small population of TCNs in motor cortex that 
respond to bilateral FGF-2 blockade with higher GAP-43 upregulation than parietal 
TCNs.  Thus the GAP-43 expression levels from medial neurons would be skewed 
upwards by a combination of both effects in the bilateral antibody infusion subgroup, but 
only by the motor neuron effect in the callosotomy with ipsilateral antibody infusion 
subgroup. 
 
3.3.5  Laminar Location of Transcallosal Neurons and Levels of GAP-43 Expression 
 In rodents, transcallosal neurons are found relatively evenly distributed between 
cortical layers II/III and V. (Conti and Manzoni, 1994; Swanson, 2003)  The assembly of 
the topographic organization of the neocortex is time dependent in development, such 
that neurons residing in different layers are born at different times.(Bielas et al., 2004)  It 
is therefore possible that the transcallosal neurons in layer II/III and those in layer V may 
consist of distinct populations of neurons with differing properties. 
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 Individual TCNs in the control, bilateral antibody infusion, callosotomy without 
antibody infusion, and callosotomy with ipsilateral antibody infusion subgroups were 
sorted by visual inspection according to their position relative to cortical layer IV.  All 
supragranular TCNs were considered to be in layer II/III while infragranular neurons 
were classified as belonging to layer V.  For a small number of neurons that appeared to 
be in medial motor cortex where cortical layer IV was indistinct, the dividing line was 
arbitrarily estimated using the level of the layer III/IV junction in the neighbouring lateral 
parietal cortex.  The mean levels of GAP-43 expression were determined for layer II/III 
and layer V neurons and compared to see if there were any significant differences.  These 
results are shown in table 3.4 and figure 3.13. 
 
Table 3.4:  Differences in levels of GAP-43 expression observed in transcallosal neurons 
in cortical layer II/III and V 
Experimental Sub-group Proportion Mean GAP-43 Expression Magnitude 
    Layer V(%)     increase 
          (X control) 
Layers      II/III  V  II/III V 
 
Control   43.7 ± 3.0   5.44 ± 0.37   7.21 ± 0.63  
Bilateral antiFGF-2*  49.2 ± 6.2 10.20 ± 0.48 13.19 ± 0.69 1.88 1.83 
Callosotomy with antiFGF-2 47.0 ± 4.6 10.76 ± 0.41 15.35 ± 0.74 1.98 2.13 
Callosotomy with PBS 38.4 ± 0.5   5.95 ± 0.53   8.12 ± 0.99 1.09 1.13 
* the concentration of antiFGF-2 in all experimental sub-groups using antiFGF-2 was 9.0 ug/mL 
 
 Statistically significant differences were found between the mean levels of GAP-
43 expression in layer II/III compared to layer V in the bilateral antibody infusion and 
callosotomy with antibody infusion experimental sub-groups (p = 0.009 and p = 0.01 
respectively).  A significant difference between layers was also found in the pooled 
control group (p = 0.03). No significant difference in levels of GAP-43 expression was 
found between layers II/III and layer V in the callosotomy with saline vehicle 
experimental sub-groups (p = 0.15) although there was a trend towards higher expression 
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in layer V.  
 
Figure 3.13:  Comparison of mean GAP-43 expression between cortical layers II/III versus V. 
 
 When the labeled transcallosal neurons in their separate layers are sorted into 
subpopulations with no, low, moderate, and high levels of GAP-43 expression, in layer 
II/III, 15.7 +/- 2.9 % were found to be unlabeled, 41.5 +/- 1.6 % had low levels of GAP-
43 expression, 25.8 +/- 1.3 % had moderate levels of GAP-43 expression, and 17.0 +/- 
2.4 % had high levels of GAP-43 expression.  In layer V, 9.6 +/- 1.3 % of the 
transcallosal neurons were unlabeled, 29.7 +/- 5.0% had low levels of expression, 27.2 
+/- 1.5% had moderate levels of expression, and 33.4 +/- 4.0% had high levels of 
expression.  The comparison in the proportion of neurons with varying levels of GAP-43 
expression between layers II/III and V is illustrated in figure 3.14 
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Figure 3.14:  Comparison of the proportion of TCNs with different levels of GAP-43 expression between 
cortical layers II/III versus V for the bilateral antibody infusion experimental sub-group. 
 
 A very similar pattern of distribution comparing layer II/III and layer V was 
found in the callosotomy with antibody infusion experimental sub-group.  Here, in layer 
II/III, 17.7 +/- 1.4 % of neurons were unlabeled, 37.5 +/- 3.0 % had low levels, 20.7 +/- 
3.1 % had moderate levels, and 24.1 +/- 4.5 % had high levels of GAP-43 expression, 
while in layer V, 9.3 +/- 2.6 % were unlabeled, 22.4 +/- 2.8 % had low levels, 25.1 +/- 
0.4 % had moderate levels, and 43.2 +/- 2.5% had high levels of GAP-43 expression.  
The comparison between the two layers for this experimental sub-group is illustrated in 
figure 3.15. 
 In both the bilateral antibody infusion and the callosotomy with antibody infusion 
experimental sub-groups, the highest proportion of layer II/III transcallosal neurons had 
low levels of GAP-43 expression, while in layer V, the highest proportion of neurons had 
high levels of GAP-43 expression.  Significantly more neurons had high levels of GAP-
43 expression in layer V than in layer II/III in both experimental sub-groups (p = 0.01 
and p = 0.03 respectively).   
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Figure 3.15:  Comparison of the proportion of TCNs with different levels of GAP-43 expression between 
cortical layers II/III compared versus V for the callosotomy with antibody infusion experimental sub-group. 
 
 The callosotomy with antibody infusion sub-group also had significantly more 
neurons with low levels of GAP-43 expression in layer II/III than layer V, (p = 0.02), 
while there was a trend to more neurons with low levels of GAP-43 in layer II/III in the 
bilateral antibody infusion group. (p = 0.07)  There was a trend towards a higher 
proportion of unlabeled neurons in layer II/III compared to V, (p = 0.08 and p = 0.06) 
while there was no significant difference between layers in the proportion of neurons that 
had moderate levels of GAP-43 expression (p = 0.17 and p = 0.30).  When the bilateral 
antibody infusion and callosotomy with antibody infusion experimental sub-groups are 
compared with each other, there were no significant differences between them in the 
proportion of neurons with no, low, or moderate levels of GAP-43 expression, and a 
trend towards a higher proportion of neurons with high levels of GAP-43 in the 
callosotomy with antibody infusion sub-group. (For unlabeled neurons, p = 0.56 for layer 
II/III and p = 0.92 for layer V; for neurons with low levels of expression, p = 0.32 for 
layer II/III and p = 0.25 for layer V; for neurons with moderate levels of expression, p = 
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0.24 for layer II/III and p = 0.22 for layer V; for neurons with high levels of expression, p 
= 0.26 for layer II/III and p = 0.08 for layer V). 
 In both the bilateral antibody infusion and callosotomy with antibody infusion 
experimental sub-groups, the proportion of transcallosal neurons that are found in layer V 
was found to increase as the level of GAP-43 expression increases.  This is illustrated in 
figure 3.16.  In the bilateral antibody infusion sub-group, the proportion of layer V 
neurons was 39.8 +/- 6.2 % in unlabeled neurons, 42.0 +/- 8.6 % in neurons with low 
levels of expression, 51.3 +/- 6.1 % in neurons with moderate levels of expression, and 
66.0 +/- 3.2 % in neurons with high levels of expression.  A trend towards a higher 
proportion of layer V neurons was found between neurons with high and low levels of 
GAP-43 expression, (p = 0.05) and the proportion of layer V neurons was significantly 
higher in neurons with high levels of GAP-43 expression when compared to unlabeled 
neurons. (p = 0.01) 
 
 
Figure 3.16:  The proportion of transcallosal neurons in cortical layer V in neuronal subpopulations with 
varying levels of GAP-43 expression. 
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 In the callosotomy with antibody infusion sub-group, the proportion of layer V 
neurons was 31.8 +/- 8.9 % in unlabeled neurons, 34.7 +/- 5.6 % in neurons with low 
expression, 52.3 +/- 6.5 % in neurons with moderate expression, and 62.0 +/- 2.3 % in 
neurons with high expression.  A significant difference in the proportion of layer V 
neurons were found between neurons with high and neurons with low levels of GAP-43 
expression, (p = 0.03) and a trend towards a higher proportion of layer V neurons was 
found when comparing neurons with high levels of GAP-43 expression with unlabeled 
neurons. (p = 0.07) 
 Thus, it appears that TCNs in layer V have a higher level of GAP-43 expression 
than TCNs in layer II/III.  After bilateral interruption of FGF-2 signaling, a significantly 
higher proportion of layer V neurons display high levels of GAP-43 expression, while a 
plurality of layer II/III neurons show only low levels of GAP-43 expression.  Also, the 
proportion of neurons that are in layer V is higher among neurons with high levels of 
GAP-43 expression after bilateral FGF-2 blockade than among neurons with lower levels 
of GAP-43 expression.  These observed differences may be merely due to a greater shift 
towards higher levels of GAP-43 expression in layer V neurons, resulting in greater 
relative numbers in the highest of arbitrarily determined groups, but may also suggest the 
possibility that bilateral FGF-2 blockade negatively affects the survival of layer II/III 
neurons relative to layer V neurons. 
 For both layer II/III and layer V, however, the magnitude of the increase over the 
control group was similar. (1.88 versus 1.83 times control in the bilateral infusion 
subgroup, and 1.98 versus 2.13 times control in the callosotomy and ipsilateral infusion 
subgroup.)  Because a significant difference between mean GAP-43 expression already 
existed in the pooled control group, the observed differences in the proportions of 
neurons with high and low levels of GAP-43 expression between layers II/III and V in 
the experimental subgroups may not represent any real difference in the response of these 
neurons to bilateral FGF-2 blockade, but simply equivalent magnifications of pre-existing 
differences in constitutive GAP-43 expression.  
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DISCUSSION AND CONCLUSIONS 
 
4.0  FGF-2 AS A RETROGRADE REPRESSOR OF GAP EXPRESSION IN 
TRANSCALLOSAL NEURONS 
 
 Our results provide evidence that GAP expression in at least one population of 
neurons in the mature central nervous system is subject to regulation by the mechanism 
of retrograde repression, which had previously been postulated to operate in the 
peripheral (Bisby, 1988; Schreyer and Skene, 1993) developing central nervous system. 
(Karimi-Abdolrezaee and Schreyer, 2002).  We have found evidence that in parietal 
transcallosal neurons, one of the substances involved in the retrograde repression signal 
in vivo is FGF-2.  At least some subpopulations of transcallosal neurons up-regulate 
GAP-43 expression when FGF-2 signaling is blocked.   
 Our results are consistent with in vivo experiments that show that FGF-2 inhibits 
process outgrowth in cultured transcallosal neurons, (Catapano et al., 2004) and stand in 
contrast to observations of the actions of FGF-2 observed in amphibian retinal ganglia 
neurons, where FGF-2 has been shown to promote GAP expression after injury. (Soto et 
al., 2003) 
 Evolutionary differences between amphibians and mammals may partly account 
for some of these observations.  After all, mature amphibian CNS neurons are known to 
possess a greater capacity for axon regeneration than their mammalian CNS counterparts.  
FGF-2 may well act as a promoter of GAP-43 expression in amphibian retinal ganglion 
cells, but as a retrograde repressor in mammalian transcallosal neurons.  Also, in the Soto 
experiments, FGF-2 was exogenously applied directly to the transected optic nerve 
stumps as a single 5 minute pulse immediately after the injury (Soto et al., 2003), while 
in our experiments, the activity of endogenous FGF-2 was blocked continuously over the 
entire course of the experiment.  These differences in technique may have contributed to 
 68
the different results.  For example, FGF-2 may be present endogenously at only very low 
levels, and act as a retrograde repressor in low concentrations, but may have an opposing 
activity when applied exogenously in high concentrations. 
 It is not necessarily surprising that the activity of any given signaling agent in one 
given neuron population would turn out to be different in a different neuron population.  
In fact, differential responses among different axon populations should be expected.  
Axon tracts converge and diverge throughout the CNS and are often precisely targeted to 
sites in close proximity to one another.  It makes perfect sense for a signaling molecule to 
promote elongation for one population of axons at a given time and place, while 
simultaneously repressing growth in another axon population, or even change from 
promotion to repression or vice versa for the same axon population at different times.  In 
this regard it is likely that FGF-2 may be acting as an initiator of a wide range of 
downstream effects acting differently on different populations of neurons and glial cells 
in the central nervous system. 
  
4.1  BILATERAL BLOCKADE OF FGF-2 IS NECESSARY FOR UP-REGULATION 
OF GAP-43 EXPRESSION TO OCCUR 
 
 A significant elevation of GAP-43 levels was observed only after a bilateral 
blockade of FGF-2 signaling.  It was necessary for both ipsilateral and contralateral FGF-
2 signaling to be blocked.  No significant differences were observed between 
pharmacologic contralateral blockade with antibody infusion versus physical contralateral 
blockade with callosotomy.  The only thing that mattered was whether or not the 
ipsilateral action of FGF-2 was also simultaneously blocked. 
 This supports our hypothesis that the presence of sustaining collaterals acts to 
maintain retrograde repression in the CNS and prevent GAP up-regulation after injury.  
GAP-43 expression did not increase in all experimental sub-groups with unilateral FGF-2 
blockades, whether pharmacologic or physical, ipsilateral or contralateral.  Retrograde 
repression appeared to remain active so long as FGF-2 signaling remained intact at the 
axon targets of at least one hemisphere, and no significant elevation of GAP-43 
expression was observed. 
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 The results from the experimental sub-group that had incomplete callosotomies 
supports the idea that actual interruption of retrograde signaling was required to 
substantially up-regulate GAP-43 expression.  Reactive scarring and other injury effects 
in the midline cortex and glia surrounding the corpus callosum was not sufficient, if the 
majority of axons remained physically in continuity and no contralateral antibody 
infusion was used to block FGF-2 action at the target sites.  Also supporting this 
hypothesis is the observation that ipsilateral anti-FGF-2 infusion alone does not result in 
significant up-regulation of GAP-43.  This indicates that the FGF-2 does not act directly 
on the transcallosal neuron cell body, but instead is active at axon target sites, and the 
signal is carried to the neuron cell body by retrograde axonal transport.   
 No positional effects suggestive of a concentration gradient of antibody were 
observed.  The location of the TCN cell body in relation to either the infusion site or the 
midline did not have any noticeable impact on GAP-43 expression.  Several factors may 
account for this observation.  Firstly, the antibody may have diffused far enough within 
the brain that concentration differences between labeled neurons closer and further from 
the injection site became insignificant.  Secondly, there may have been a threshold 
concentration needed for the antibody to block FGF-2 signaling in affected neurons, 
above which no further effects would be observed, and this threshold concentration was 
reached for the majority of the neurons sensitive to FGF-2 blockade that were analyzed.  
Thirdly, these results may have been confounded by the fact that it is the concentration of 
antibody found at the axon target sites, and not the cell body, that would be most 
important in blocking retrograde repression, and the terminal axon arborizations of the 
analyzed transcallosal neurons may have been sufficiently spread out within the area 
through which the antibody diffused that the actual location of the neuron cell body did 
not matter. 
 The lack of observable positional effect also reduces the possibility that 
limitations to precision inherent in the surgical technique had any significant impact on 
the results.  Variations in the precise implantation sites on ipsilateral and contralateral 
sides relative to each other, and between implantation sites from experimental animal to 
experimental animal might have been expected to result in individual transcallosal 
neurons being exposed to differing concentrations of antiFGF-2 at their contralateral and 
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ipsilateral axon target sites.  This imprecision may therefore have contributed to some of 
the observed differences in GAP-43 expression observed between individual transcallosal 
neurons.  The lack of any distance effect seen in the callosotomy with antibody infusion 
experimental sub-group argues against this possibility.  The transcallosal neurons in this 
sub-group should in theory have experienced a complete and total blockage of 
contralateral signals due to the callosotomy, so that the only the ipsilateral axon target 
sites would have been affected by concentration dependent effects of the ipsilateral 
antibody infusion.  The lack of difference in observed GAP-43 expression levels between 
neurons near the infusion site, where the concentration of antibody should have been 
highest, and those far away from the infusion site, where the concentration of antibody 
would have been lower, suggests that the range of diffusion of the antibody within the 
cortex in the individual animals was wide enough that concentration effects were not 
significant.   
 Our results are consistent with the findings of previous experiments involving 
DRG neurons where an up-regulation of GAP expression did not occur after central 
axotomy when the peripheral axon branch was left undamaged and allowed to act as a 
sustaining collateral. (Schreyer and Skene, 1993)  Similarly, we found that GAP-43 
expression was not up-regulated after any form of unilateral FGF-2 blockade, presumably 
because intact axons from the unaffected side continued to act as sustaining collaterals. 
 In DRG neurons, the peripheral axon appears to provide retrograde repression 
signals for both itself and the central axon.  Peripheral axotomy alone results in an up-
regulation of GAP expression and an improvement in the regenerative capacity of the 
central axon into permissive environments. (Richardson and Issa, 1984; Richardson and 
Verge, 1986)  Our results with transcallosal neurons supports our hypothesis that in CNS 
neurons, multiple axon branches act as sustaining collaterals in concert, such that all must 
be disconnected before the retrograde repression of GAP expression is lifted, and that this 
difference in morphology accounts at least in part for some of the observed difference in 
regenerative capacity between PNS and CNS neurons. 
 Another difference observed between PNS and CNS neurons is the effect that the 
distance between the neuron cell body and the axotomy site has on regenerative capacity.  
In PNS neurons such as DRG cells (Liabotis and Schreyer, 1995) and spinal 
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motoneurons, (Fernandes et al., 1999) axotomy distance has no measurable effect on 
GAP expression or regeneration.  In contrast, the few CNS neuron populations known to 
be capable of some regenerative response after axotomy invariably can only do so if the 
axotomy is proximal.  For example, retinal ganglion cells in rats can regenerate axons 
into a permissive environment if the axotomy is within 3 mm of the eye but not beyond, 
(Doster et al., 1991) and rubrospinal neurons both up-regulate GAP-43 expression 
(briefly) and regenerate into a permissive environment following a cervical axotomy but 
not a thoracic one. (Fernandes et al., 1999)  
 The differing capacities for regenerative responses in CNS neurons after proximal 
versus distal axotomy has been attributed to the summation of negative signals provided 
by CNS myelin.  The more distal the axotomy, the more CNS myelin and associated glial 
cells remain to provide more inhibition of regenerative responses.  Our results suggest 
that neuronal morphology may provide an alternative or additional explanation.  The 
more proximal the axotomy, the greater proportion of the neuron’s axon collateral 
arborization is likely to be disconnected.   
 Another question that arises is whether or not the retrograde repressive acts as a 
summation of all signals received from the various axon collaterals, such that the greater 
the total signal, the greater the degree of inhibition of GAP expression, or instead in an all 
or nothing fashion with some specific threshold of signal above which GAP expression in 
suppressed.  Experimental findings to date can be interpreted in both ways.  In retinal 
ganglion cells, a proximal axotomy close to the eye would be highly likely to sever all of 
the axon collaterals, since the major collaterals branch off post-chiasmatically. (Felton 
and Jozefowicz, 2003)  On the other hand, the rubrospinal tract innervates interneurons in 
the facial nerve nucleus and lateral reticular nucleus in the brainstem, and the anterior 
horn of the spinal cord in regions that project motor neurons to the muscles of the limbs. 
It is more difficult to determine whether or not a proximal axotomy at the cervical spine 
would interrupt the totality of retrograde signaling for any given rubrospinal neuron.  It 
seems likely that a majority of axon collaterals would be disconnected, but the possibility 
would always remain that some axon collaterals still remain even more proximal to the 
axotomy.   
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 Both explanations can also account for the variability in response observed in our 
experiments.  Transcallosal neurons with widespread axon collaterals beyond the zone of 
antibody activity may have received varying amounts of intact retrograde signal.  
Alternately, different populations of transcallosal neurons may be responding differently 
to FGF-2, with different thresholds of sensitivity to FGF-2 blockade resulting in different 
levels of GAP-43 expression, and some TCNs may be insensitive to FGF-2, and are 
governed by a different retrograde repressor.  
 The average degree of elevation of GAP-43 expression we observed in our 
experiments was roughly twice the level seen in controls.  This level is substantially 
lower than the levels of increase reported for some peripheral neurons, which are often 
ten or more times greater than unlesioned controls.(Bisby, 1988; Tetzlaff et al., 1991; 
Fernandes et al., 1999)  This difference is consistent with the reduced ability of CNS 
neurons to mount regenerative responses after injury compared to PNS neurons.  
However, our GAP-43 expression levels were measured at a single time point, 7 days 
after experimental manipulation, so it is possible that GAP-43 expression was still 
climbing at that point and had not yet peaked, or had reached a higher level earlier and 
had started to fall.  Also, the magnitude of the elevation of GAP-43 expression that was 
observed was the mean of a population with a wide variation in the levels of GAP-43 
expression in individual cells.  In the subpopulations with high levels of GAP-43 
expression, the majority of TCNs had levels of expression that were three to five times 
control, which is consistent with the levels reported for rubrospinal neurons after 
proximal axotomy. (Fernandes et al., 1999)  A few neurons were observed with levels of 
GAP-43 expression five to ten times controls, but no neurons were observed with levels 
of expression that exceeded ten times the control levels.  
  
4.2  THE INHIBITION OF AXON REGENERATION IN THE CNS 
 
4.2.1  Retrograde Repression as a Signal for Continuing Target Contact 
 Our results show that retrograde repression as a mechanism of regulation is active 
in the mature central nervous system, and previous experiments have demonstrated the 
same mechanism in the peripheral nervous system and the developing CNS.(Bisby, 1988; 
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Karimi-Abdolrezaee and Schreyer, 2002)  So far, retrograde repression has been shown 
to regulate the gene expression of target neurons, reducing the expression of growth 
related genes, thus affecting the early phase of the initiation of regeneration after injury.  
In the peripheral nervous system, loss of the retrograde repressive signal indicates loss of 
target contact, and allows for the initiation of axon regeneration when target contact has 
been interrupted by injury.  In the central nervous system, through the action of multiple 
sustaining collaterals, it acts to prevent the initiation of a regenerative phenotype after 
injury to some but not all of a neuron’s axon collaterals. 
 Retrograde repression may play a role in the creation of appropriate functional 
axon connections during development and the maintenance of these same connections in 
the adult.  It provides a stop signal to axon growth, such that developing axons do not 
overshoot their appropriate target tissues, and may provide some of the signals 
responsible for prompting a developing neuron to differentiate from a growth state to a 
functional state. 
 Our findings, along with previous work showing the successful induction of GAP 
expression by the interruption of retrograde axonal signaling alone (Liabotis and 
Schreyer, 1995; Bisby et al., 1996; Karimi-Abdolrezaee and Schreyer, 2002) suggest that 
retrograde repression plays a major role in the regulation of GAP expression in both the 
central and peripheral nervous systems.  Other observations clearly demonstrate, 
however, that while GAP expression might be necessary, it is not, by itself, sufficient to 
ensure successful axon regeneration. (Richardson and Issa, 1984; Vidal-Sanz et al., 1987; 
Tetzlaff et al., 1991; Davies et al., 1997b; Moon et al., 2000)  A permissive environment 
is also necessary to promote the outgrowth, extension, and guidance of regenerating 
axons after the GAP associated growth phenotype is reactivated.  While the PNS 
generally provides such a permissive microenvironment, the mature CNS does not. 
 
4.2.2 Inhibition of Regeneration Mediated by CNS Glia 
 Retrograde repression is not the only mechanism active in the adult CNS that 
inhibits axon outgrowth and regeneration after injury.  CNS glia and its associated myelin 
plays a key role in the inhibition of axon outgrowth and regeneration.  Axon outgrowth 
during development usually occurs in a myelin free environment, and CNS neurons 
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generally begin to lose the ability to robustly regenerate injured axons around the same 
time that myelination begins.(Qiu et al., 2000)  Robust regeneration of mature CNS axons 
can be induced in tracts depleted of CNS myelin. (Moon et al., 2000)  As previously 
mentioned, the increased effect of proximal axotomy on GAP up-regulation in CNS 
neurons can be alternately explained as a consequence of decreased total glial inhibition 
along the remaining short axon stump after a proximal axotomy compared to the longer 
axon stump with more associated glial cells and glial inhibition after more distal 
axotomy.  Even in the PNS, mature myelin appears to have some inhibitory action.  PNS 
axons only begin regenerating after myelin debris is cleared by Wallerian degeneration 
and the Schwann cells revert to a non-myelin producing phenotype.(Hall, 2005; Yiu and 
He, 2006)  Unlike Schwann cells, oligodendrocytes and astrocytes in the CNS do not 
seem to revert to a growth-favoring phenotype after injury. 
 A number of factors associated with CNS glia that have inhibitory effects of axon 
outgrowth have been identified, including substances such as Nogo, myelin associated 
glycoprotein (which appears to promote neurite outgrowth during development but 
becomes inhibitory in the adult), semaphorin 4D, ephrin B3, and oligodendrocyte myelin 
glycoprotein.(Qiu et al., 2000; Yiu and He, 2006)  Interestingly, many of these factors are 
sequestered within CNS myelin, and in the intact state, axonal exposure is limited.  High 
levels of these inhibitors released into the CNS microenvironment by damaged myelin 
after injury. 
 In the injured state, the glial scar provides yet another level of inhibition of axon 
regeneration.  Collateral axon sprouting from outside the area of injury has been 
observed, but even this limited attempt at regeneration invariably grows up to the site of 
injury but no further.  Reactive astrocytes infiltrating the injury site may provide a 
physical barrier to axon regrowth, and also produce their own additional inhibitory 
factors.  Experiments have shown that treatments that neutralize the activity of some of 
these inhibitors can reduce some of this inhibition and promote axon regeneration after 
spinal cord injury.(Moon et al., 2001)  The result of all these inhibitory mechanisms is 
that the mature CNS microenvironment is normally significantly hostile to axon 
outgrowth and regeneration, allowing for only limited axon collateral sprouting and 
 75
plasticity, and after injury it becomes, almost paradoxically, even more profoundly 
inhibitory.   
 
4.3  EVOLUTIONARY CONSIDERATIONS 
 Among vertebrates there is a clear pattern of progressive loss of regenerative 
capacity in the CNS over time.  Anamniotic vertebrates such as fish, newts, and 
salamanders retain a robust ability to regenerate mature CNS axon tracts after injury.  A 
reduction in regenerative capacity begins to be observed in anuran amphibians, such as 
frogs and toads, where long spinal cord axon tracts cannot regenerate after 
metamorphosis into the adult.(Skene, 1984)  Amniotic vertebrates such as birds and 
mammals possess almost no ability to regenerate CNS axons beyond embryonic 
development, although some primitive mammals such as opossums which have 
abbreviated gestations and comparatively premature births are known to retain 
regenerative capability in the CNS for a few days after birth.(Yiu and He, 2006) 
 Why should higher vertebrates have lost the ability to regenerate CNS axons 
during the course of their evolution?  The first question to consider is how much of an 
adaptive advantage the ability to regenerate CNS axons would actually be.  Axonal 
regeneration, even in the most ideal circumstances, is a long-term mechanism.  As 
vertebrates became larger and more complex, the consequences of any serious CNS 
trauma would have likely become ever more immediately catastrophic.  For the average 
early mammal (or reptile or bird, for that matter), a severe CNS injury would have 
immediately resulted in an inability to obtain food or escape from predators, and would 
consequently have been fatal within a very short time.  As such, any capacity to 
regenerate CNS axons over the long-term would not likely have provided a significant 
selective advantage.  It is possible then, that the regenerative ability inherited by the first 
amniotes from their anamniote ancestors, became over the course of time a selectively 
neutral trait, which could then be freely lost by random mutation and genetic drift. 
 However, the presence of so many active and overlapping systems in the mature 
CNS that act in concert to suppress axonal regeneration strongly suggests that 
regenerative capacity was not merely passively lost over evolutionary time, but that 
growth restriction was actively favored by natural selection.  That is, higher vertebrates 
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did not simply lose an ability to regenerate CNS axons that they no longer needed, but in 
fact gained the ability to restrict CNS axon regeneration as an adaptive evolutionary trait. 
 Why should the inability to regenerate a vital organ system be an adaptive 
response?  Perhaps it arose as a secondary consequence of the development of another 
trait that proved beneficial.  One possibility is that the inability for the adult CNS to 
regenerate axons is a consequence of the mechanisms controlling axon pathfinding 
during development.  A common mechanism of axonal guidance during development is 
for attractive factors to draw developing axon terminals into an intermediate region 
between their origin and their ultimate target, after which the attractive factors change 
into repulsive ones that drive the axons out of the first intermediate region and towards 
the next, which produces its own attractive factors that in turn become repulsive.  The 
process is subsequently repeated through any number of various intermediate areas until 
the final destination is reached.  Thus, by the time of maturity, the majority of guidance 
signals along the axon tract are negative in nature, and many of these repulsive and 
inhibitory cues persist into adulthood.(Yiu and He, 2006)  As a result, injured axons in 
the mature CNS are prevented from re-entering the same regions they traversed during 
development.  Over evolutionary time, refinements in the specificity and precision of 
these guidance mechanisms would allow for the development of larger and more 
functional body plans and more sophisticated behaviors, and provide a strong adaptive 
advantage that would be favored by natural selection.  The loss of regenerative capacities 
of limited survival value would, from an evolutionary perspective, be a small price to pay 
in exchange.    
 There may also be an intriguing link between axon regeneration and neuron 
survival after CNS injury.  Mature cerebellar purkinje cells do not regenerate axons after 
injury, even if a permissive environment is provided, but are capable of long term 
survival after axotomy.   In contrast, inferior olivary neurons whose axons are cut by the 
same lesion, up-regulate GAP expression and are capable of axon regeneration into a 
permissive environment after axotomy, but the vast majority die. (Dusart et al., 2005)  In 
these neurons, the up-regulation of GAP-43 and c-Jun appear to be associated with a 
greater likelihood of cell death as well, suggesting that an attempt at axon regeneration 
and subsequent cell death are somehow linked.  It is possible that the opposite may be 
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true, and the restriction of axon regeneration somehow promotes neuronal survival in 
injured CNS neurons.  If this is the case, it may be that the survival of CNS neurons with 
complex axon arbors and multiple synaptic connections after trauma is favored by natural 
selection over the promotion of axon regeneration if that process also increases the risk of 
cell death and the subsequent loss of all its functional connections. 
 
4.4  THE REGULATION OF PLASTICITY 
 
4.4.1 The Role of Retrograde Repression in Regulating Neuronal Plasticity 
 Another trait that may have secondarily promoted an increasing restriction of 
regenerative capacity is the development of neuronal plasticity.  All adaptive behavior is 
underpinned by plasticity within the CNS and constitutes a likely target for natural 
selection to act on.  If axon regeneration is analogous to axon long tract elongation during 
development, then plasticity in the mature CNS is analogous to axon sprouting during 
target innervation and remodeling in development.  The first process involves relatively 
rapid, straight and long process outgrowth, while the second is slower, and produces short 
processes with multiple branches.   
 Various GAPs are involved in both processes in both development (axon 
elongation and target innervation) and maturity (axon regeneration and reactive terminal 
arbor reorganization).(Wieloch and Nikolich, 2006)  These two processes, however, are 
probably distinct, and regulated by different mechanisms.(Smith and Skene, 1997)  Since 
some of the genes and proteins involved in the two processes are shared, it makes sense 
that their regulation be different and perhaps sometimes mutually antagonistic, such that 
the activation of one system does not inappropriately activate the other.  Interestingly, in 
the previously mentioned cerebellar purkinje cells, short collateral sprouting is frequently 
observed after axotomy,(Dusart et al., 2005) suggesting a link between the promotion of 
plasticity and neuron survival. 
 In this light, the substances involved in retrograde repression are likely to have 
some role in plasticity regulation as well.  Since they are thought to be produced by target 
tissues and act on the presynaptic cell, it would be highly surprising if they were not also 
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involved in plasticity in some way.  At least some retrograde repressors in this view 
should simultaneously have opposing activities, promoting terminal arbor sprouting while 
inhibiting inappropriate long axon growth during periods of terminal arbor 
reorganization.  Other retrograde repressors may also exist that act as inhibitors in both 
cases, helping to maintain stable functional connections over a long periods of time by 
limiting both continued long axon growth and unwanted collateral sprouting.  It may even 
be possible that a single retrograde repressor may perform in both ways at differing 
times.  In this scenario, retrograde repression of axon elongation would actually be a 
secondary function of a substance primarily involved in the regulation of neuronal 
plasticity. 
 The need for maintaining pre-existing functional connections and strictly 
regulating plasticity may be an important reason why regenerative responses are so 
limited in the central nervous system compared to the peripheral nervous system.  
Because CNS neurons elaborate many axon collaterals and participate in many 
interrelated neuronal circuits, it may be more important from the point of view of overall 
function to sustain pre-existing connections after traumatic injury than it is repair 
damaged axon connections, if the regenerative processes required to do so may as a side 
effect result in the disruption of other functional connections the neuron is participating 
in.  After traumatic injury, sprouting has been observed to sometimes occur from intact 
axon collaterals distant from the injury site. (Grafstein, 1975)  An instructive example are 
DRG neurons, where remote injury to the peripheral axon branch induces GAP up-
regulation that can promote the extension of pre-existing and/or the growth of new 
central axon branches into permissive environments free of other inhibitory influences, 
even if there had been no initial injury to the central axons themselves. (Richardson and 
Verge, 1986)  It is certainly possible that such new axon collaterals in a mature and 
functioning system could, if unregulated, form extraneous connections that might disrupt 
delicately balanced pre-existing circuits in a way that results in functional impairment.  
For example, the reactive sprouting of mossy fibers after a cortical insult has been 
implicated in the development of certain seizure disorders.(Chang and Lowenstein, 2003)  
Aberrant re-innervation after trauma can lead to poor functional outcomes even in the 
comparatively regeneration friendly PNS.  Retrograde repression from sustaining 
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collaterals may be one mechanism that reduces the risk of this happening, since any 
neuron still possessing sustaining collateral axon connections is likely to be still 
participating in intact and useful circuits.  From the point of view of the organism as a 
whole, it may be more beneficial to reduce the risk of developing significant functional 
distortion due to errant and/or overzealous axon regeneration in reaction to comparatively 
minor but common injuries than to promote robust regenerative capability after any 
devastating but rare injury that would significantly compromise immediate and short term 
survival irrespective of any potential for long term recovery. 
 The possibility that inhibitory processes play important regulatory roles has 
clinical implications for the treatment of CNS axonal injury.  Certainly the risk exists that 
pharmacologically eliminating or counteracting these inhibitory mechanisms in an 
attempt to promote axon regeneration may have unexpected and undesirable secondary 
effects.  An insufficiently specific and targeted attempt at treatment may well turn out to 
be akin to trying to restore a well-manicured garden that had been damaged in a fire by 
indiscriminately pouring fertilizer onto it.  There is much potential for unintended 
consequences, and inadvertently promoting the development of a seizure disorder is only 
one possibility.  Many higher level functions may turn out to be dependent on the strict 
regulation of the plasticity of the underlying neuronal circuitry, and highly sensitive to 
even small disruptions.  However, the evolutionary consideration also raises the 
intriguing possibility that evolutionarily primitive but desirable functional capabilities 
such as improved bowel and bladder control, or independent respiration after severe high 
spinal cord injury(Yiu and He, 2006) may be comparatively robust and would be 
preferentially preserved by relatively simple manipulations of the inhibitory mechanisms 
preventing CNS axon regeneration. 
 
4.4.2  The Role of GAP-43 and FGF-2 in Neuronal Plasticity 
 As previously mentioned, the developmental downregulation of GAP-43 
expression is biphasic, with decreasing expression occurring when growing axons first 
contact target tissue, and later upon the maturation of the terminal arborization. (Karimi-
Abdolrezaee et al., 2002)  This suggests that GAP-43 is involved in both the process of 
axon elongation and the later process of terminal branching, and supports the hypothesis 
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that the two processes are regulated by distinct mechanisms.  Given this role in terminal 
arborization, it is not surprising that GAP-43 has been implicated in neuronal plasticity in 
the mature CNS.(Strittmatter et al., 1992; Benowitz and Routtenberg, 1997)   
 Interestingly, there is evidence to suggest that FGF-2 is also involved in neuronal 
plasticity in the adult, and that it acts to promote the process.  Studies have shown that 
treatment with FGF-2 can promote the recovery of sensorimotor function after MCA 
infarction in rodents, when administered both immediately after the ischemic insult, or 
later in a delayed fashion.(Kawamata et al., 1996)  Early administration of FGF-2 appears 
to enhance neuronal survival and the proliferation of neuronal stem cells, and results in a 
reduction of the size of the infarct.  However, functional improvement can also be seen 
after late administration, in which case the infarct size does not change.  In this case, an 
increase in GAP-43 is observed in the ipsilateral peri-lesional area, and in the 
contralateral sensorimotor cortex, suggesting the possibility that the functional 
improvement is due to the plastic development of compensating collateral 
connections.(Kawamata et al., 1997)  Furthermore, this functional improvement does not 
occur if GAP-43 function is silenced with anti-sense mRNA.(Kawamata et al., 1999) 
 Comparing these results with our results leads to some interesting speculation.  In 
both cases, an increase in GAP-43 expression was observed, but in one case this was as a 
result of FGF-2 administration, while in the other, it was a response to FGF-2 blockade.  
One possibility is that these seemingly paradoxical results are due to differences in the 
experimental situations.  In the experiments of the Kawamata group, the increase of 
GAP-43 expression was seen in brains subject to widespread ischemic injury, while our 
experiments involved intact cortex.  Metabolic changes as a result of ischemia may have 
altered the normal neuronal response to FGF-2, or FGF-2 may have promoted the 
survival of neuronal populations with higher baseline GAP-43 expression, resulting in a 
relative increase in GAP-43 levels.  In the Kawamata experiments, FGF-2 was 
administered intracisternally, and presumably distributed throughout the CNS, while in 
our experiments, FGF-2 activity was blocked in a local cortical area.  As in the case of 
the positive response to FGF-2 administration in frog retinal ganglion cells, dosage 
related effects, wherein one case a relatively high level of FGF-2 is exogenously 
administered, while in the other case the activity of a low level of endogenous FGF-2 is 
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blocked, may have contributed to the difference in results.  The Kawamata group also 
quantified GAP-43 expression using GAP-43 protein rather than GAP-43 mRNA.  Since 
GAP-43 is transported to and concentrated in elongating axon terminals, it is not clear 
whether or not the observed GAP-43 protein was produced in the local cortex or 
transported there from distant sites induced by the global exposure to FGF-2.  Either way, 
the specific neuronal population in which GAP-43 expression is up-regulated is not 
known, so the elevated GAP-43 levels observed may not have been produced by 
transcallosal neurons, but by another neuronal population that responds to FGF-2 in an 
opposite fashion. 
 Another possibility worth considering is that different results were observed 
because different mechanisms were investigated.  That is, in the Kawamata experiments, 
GAP-43 was up-regulated by FGF-2 in relation to the promotion of neuronal plasticity, 
while in our experiments, FGF-2 was acting to inhibit GAP-43 expression in relation to 
limiting axon elongation.  If this is true, then FGF-2 may be one of the postulated 
substances with a dual role, acting to enhance collateral sprouting in relation to plasticity, 
while also inhibiting long tract regeneration as a retrograde inhibitor.  In this light, the 
activity of FGF-2 in developmental axon guidance is suggestive.  Its ability to inhibit the 
forward movement of the primary growth cone in order to promote the development of 
collateral branching(Szebenyi et al., 2001) is exactly the kind of mechanism one might 
expect to see in a substance that acts both as a retrograde repressor of axon long tract 
regeneration and a promoter of collateral sprouting in plasticity. 
 Another possible resolution of the apparent conflict in our results is seen when the 
areas of cortex where GAP-43 up-regulation was observed is compared between the 
Kawamata experiments and our experiments.  The area of the MCA territory infarction 
zones in the Kawamata experiments included within it the area of contralateral minipump 
implantation in our experiments.  Up-regulation of GAP-43 was seen ipsilaterally in the 
motor cortex medial to the infarction zone, and contralaterally in the homologous medial 
motor cortical area.  However, elevated GAP-43 levels were not detected contralateral 
parietal cortex that was homologous to the infarct site,(Kawamata et al., 1997) which was 
the area that we studied, even though the infarct in the other hemisphere destroyed the 
transcallosal target site.  This is exactly what one should expect if our hypothesis that 
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FGF-2 represses GAP-43 expression in transcallosal neurons in the parietal sensory 
cortex is correct.  The Kawamata results also suggest a possible explanation for the trend 
we observed towards slightly higher GAP-43 expression in medial TCNs compared to 
lateral TCNs.  The mean levels of GAP-43 expression may have been increased in some 
of the medial neurons due to a plasticity reaction to the infusion site trauma. 
 Taken together, the results of our experiment and those reported by the Kawamata 
group may be demonstrating that FGF-2 has opposite effects on two neighbouring 
regions of sensorimotor cortex, promoting GAP-43 expression in the medial and largely 
motor areas while repressing GAP-43 in the more lateral and largely sensory areas.  FGF-
2 may therefore by involved in keeping some of the axon tracts related to motor and 
sensory cortex separate, preventing inappropriate cross connections between the motor 
and sensory areas of the brain. 
 
4.5 FUTURE DIRECTIONS 
 
4.5.1  The Rat Transcallosal Neuron as an Experimental Model and Proposed 
Refinements of the Experimental Technique 
 These experiments demonstrate the usefulness of the TCN of the rat as an 
experimental model for studying the regulation of GAP expression in the mammalian 
CNS.  The TCNs were easily identified using retrograde fluorescent tracers.  Although 
the fluorescent stain had a tendency to be washed out of the sections during subsequent 
processing, necessitating the creation of fluorescent cortical maps prior to in situ 
hybridization, this proved to be only a minor technical inconvenience.   
 The homologous nature of the transcallosal projection (Cracco et al., 1989; 
Swanson, 2003) allowed for the specific targeting of both ipsilateral and contralateral 
axon termination sites through the use of stereotactically implanted osmotic mini-pumps.  
One problem encountered during mini-pump implantation in these experiments was the 
imprecision involved in separately implanting the ipsilateral and contralateral mini-pump 
brain cannulae in the bilateral infusion experiments.  Motion of the brain cannulae after 
placement but prior to complete fixation during manual implantation also contributed to 
increased amounts of tissue damage and scarring at the infusion site.  
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Figure 4.1:  Proposed scaffold for bilateral mini-pump implantation.  View from above (top) and view from 
side (bottom).  Brain infusion cannulae are attached to scaffold, and entire construct stereotactically 
implanted in a single step, with point B positioned over Bregma.  Scaffold then detached along with 
detachable knobs of Alzet osmotic mini-pump brain infusion cannula head. 
 
 For future bilateral infusions, both brain infusion cannulae can be attached prior 
to implantation to the ends of a sterile scaffold, as shown in figure 4.1.  The scaffold can 
be made of wood or steel wire, or possibly even hard rubber, which would allow it to be 
pierced by a syringe needle which could subsequently be attached to the stereotactic 
frame arm.  After attachment to the stereotactic arm, the entire construct is positioned 
with its center over the midline at the desired AP distance relative to Bregma, allowing 
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both the ipsilateral and contralateral brain infusion cannulae to be placed simultaneously, 
and held motionless by the frame until fixed into place by the polyacrylamide glue, after 
which the scaffold can be detached from the implanted brain cannulae.  The shape and 
size of the scaffold can be modified to allow for implantations if different sites are 
required or animals of different sizes are used. 
 The corpus callosum proved to be a readily accessible site for experimental 
lesioning.  In these experiments, partial callosotomies were performed, with only the 
anterior corpus callosum sectioned, and the posterior portion left intact in order to 
minimize injury to midbrain structures lying directly below the posterior third of the body 
of the corpus callosum.  Extending the callosotomy to include the posterior portion of the 
corpus callosotomy would be technically relatively simple, although it may carry an 
increased risk of morbidity to the experimental animals.   
 The assumption was made that the majority of transcallosal fibers projecting from 
the cortical area of interest would cross the midline without first traveling parallel to the 
corpus callosum any significant distance in the anterior-posterior plane, such that axons 
originating from neurons in the parietal cortex around -0.8 mm to Bregma would cross in 
the corpus callosum within the anterior-posterior extent of the callosotomy section (from 
1.2 mm to Bregma to -2.8 mm to Bregma, or 4 mm total centered on -0.8 mm to 
Bregma), such that the anterior callosotomy would be sufficient to section the majority of 
these axons.  If there was any significant subpopulation of axons that did not do this, but 
traveled posteriorly for a significant distance and crossed the midline in the posterior 
third of the corpus callosum, then these axons may account for some of the neurons that 
were observed to remain with low levels of GAP-43 expression in the callosotomy 
experiments, since these neurons would not have had their contralateral FGF-2 signaling 
interrupted by the callosotomy.  However, FGF-2 signaling in these neurons should still 
have been interrupted by contralateral antibody infusion, so these neurons would still 
have been exposed to bilateral FGF-2 blockade in the bilateral antibody infusion 
experiments.  The fact that no significant differences in the levels of GAP-43 expression 
were observed between the bilateral infusion and callosotomy with infusion experimental 
sub-groups argues against neurons with this sort of axon morphology having a significant 
impact on the overall results.    
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  The degree of tissue damage in the midline cortex associated with callosotomy in 
these experiments was not insignificant.  However, the presence or absence of a 
callosotomy scar did not produce any noticeable effects in these experiments.  The level 
of GAP-43 expression in the experimental subgroup receiving callosotomy without 
antibody infusion was not significantly different than the control groups that did not have 
callosotomies.  The two animals that had incomplete callosotomies also did not have 
GAP-43 expression levels substantially different from the controls, even though the size 
of the callosotomy scar in these animals was essentially no different from animals 
receiving complete callosotomies, except for the absence of complete transection of the 
corpus callosum itself.  Finally, there was no significant difference between the 
experimental subgroup that received callosotomy and antibody infusion and the subgroup 
that was treated with bilateral antibody infusion, in which there was no callosotomy scar. 
 The size of the midline callosotomy scar could be reduced in future experiments 
by using a finer callosotomy knife.  Alternatives to the 25 gauge syringe needle used in 
these experiments that can be considered include a stereotactic wire knife, a fine scalpel 
blade such as a Beaver blade, or simply a finer gauge syringe needle. 
 Although not attempted in this study, methods are also available for isolating and 
culturing transcallosal neurons, allowing them to be studied under controlled in vitro 
conditions.(Catapano et al., 2004)  Other potential substances of interest besides FGF-2 
can have their effects on transcallosal neurons studied in vitro prior to in vivo 
experimentation. 
 Aside from being just an experimental model, the transcallosal neurons 
themselves are a subject on which further scientific study is warranted.  In addition to 
being prototypical excitatory pyramidal projection neurons, they are subject to dysgenesis 
and degeneration in a variety of conditions, with many implications for human 
health.(Catapano et al., 2004)  From a clinical perspective, injury to the corpus callosum 
in humans is often seen in the setting of head trauma, and may also occur as a 
consequence of the rupture of midline aneurysms, or infarction in the territories of the 
distal branches of the anterior cerebral arteries.  The deliberate transection of the corpus 
callosum is a neurosurgical procedure sometimes indicated for the improved control of 
intractable seizures, and disconnection syndromes are a recognized adverse outcome, 
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particularly if the posterior third of the corpus callosum is damaged.  Neurosurgeons also 
use transcallosal approaches to access pathology involving the lateral and sometimes the 
third ventricles, and inadvertent injury to portions of the corpus callosum can occur in 
these procedures.  
  
4.5.2  The Effect of Time on Neuronal Response to Bilateral FGF-2 Blockade 
 In these experiments, an increase in GAP-43 expression in response to bilateral 
FGF-2 blockade was observed at a single time point, 7 days after the initiation of the 
blockade.  The timing of GAP responses after axonal injury has been documented in 
other known experimental systems.  In frog and goldfish retinal ganglion cells, GAP-43 
synthesis begins to increase 4 to 5 days after injury and reach peak levels 10 to 14 days 
after injury, and fall back to background levels 5 to 10 weeks after axotomy, usually after 
axon regeneration is complete.(Skene and Willard, 1981b; Skene, 1984)  Levels of GAP-
43 in rat retinal ganglion cells were observed to be elevated between days 6 to 26 after 
intraorbital axotomy near the neuron cell body.(Doster et al., 1991)  In rat facial 
motorneurons, GAP-43 mRNA expression peaked at 7 days post lesioning and remained 
at that level for more than three weeks, while in rubrospinal neurons, GAP-43 expression 
also peaked at 7 days after injury, and remained elevated even at 7 weeks after injury, but 
declined from the peak level of expression as the neurons were observed to 
atrophy.(Tetzlaff et al., 1991) 
 This suggests but does not confirm that the level of GAP-43 expression measured 
7 days post FGF-2 blockade in our experiments would be likely at or near the peak of 
GAP-43 up-regulation.  In order to investigate the timing of GAP-43 up-regulation after 
FGF-2 blockade, bilateral antibody infusion and callosotomy with antibody infusion 
experiments can be performed with infusion times of varying length.  Based on the 
available data from other neuron populations, potential time intervals worth investigating 
might be 3 days, 7 days, 2 weeks, 4 weeks, and 6 weeks, although longer time intervals 
may require several interval replacements or refilling of the implanted mini-pumps.  In 
this fashion, it can be determined how soon after FGF-2 blockade is the up-regulation of 
GAP-43 is initiated, how quickly GAP-43 mRNA levels rise, when and at what level 
does it peak, how long GAP-43 expression is sustained at high levels, and how long, if 
 87
ever, it takes for levels of GAP-43 expression to decrease back to baseline levels.  
Comparisons can be made between bilateral antibody infusion and callosotomy combined 
with ipsilateral antibody infusion to determine if there are any differences in the timing 
and magnitude of the response between the two groups.  Further information can also be 
obtained with regards to neuronal survival and atrophy over time. 
  
4.5.3  Other GAPs and Other Proteins 
 In these experiments, GAP-43 was used as a marker for GAP expression in 
general, on the assumption that increased levels of GAP-43 expression would be 
accompanied by increased levels of expression of other growth associated proteins.  
Because GAP-43 and FGF-2 both appear to be involved in both axon regeneration and 
plastic collateral sprouting, GAP-43 may not necessarily be the ideal marker to sort out 
the activity of these two processes in the TCN system.  Thus the effect of bilateral FGF-2 
blockade on the levels of expression of mRNAs of other GAPs would be worthwhile.  
This can be easily done by using cDNA probes for other GAPs for in-situ hybridization.  
Candidates for investigation would include GAP-24 (Skene and Willard, 1981a), alpha 
and beta-tubulin (Skene and Willard, 1981a). 
 The most interesting to investigate may be the GAPs that act as transcription 
factors, such as c-Jun (Jenkins and Hunt, 1991), Jun-D, and activating transcription factor 
3, since these proteins are probably involved in the coordination of the generalized 
growth response. 
 The expression of non-GAP proteins known to be produced by mature 
functioning TCNs would also be worth investigating to see what other effects on the 
normal TCN phenotype bilateral FGF-2 blockade might have.  Such substances might 
include peptide neurotransmitters known to be produced by TCNs such as Substance P, 
(Conti and Manzoni, 1994) or the metabotropic glutamate receptor.  Since transcallosal 
neurons continue to maintain axon collaterals to local targets after distal axotomy, and the 
possibility that retrograde repression may play a role in the regulation of plasticity and 
the maintenance of functional connections, it would be interesting to investigate whether 
bilateral FGF-2 blockade would result in the down-regulation of proteins associated with 
the mature and functional neuronal phenotype. 
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4.5.4  Subpopulation Investigation 
 It was clear that individual transcallosal neurons were responding differently to 
the FGF-2 blockade in our experiments, and that the varying responses were falling in a 
gradient from low to high levels of GAP-43 expression.  The population histograms did 
not reveal any obvious second peaks that might have identified any one specific sub-
population of neurons that were particularly responsive, or non-responsive, to FGF-2 
blockade.  The possibility remained that several sub-populations of transcallosal neurons 
exist with differing degrees of sensitivity to retrograde repression from FGF-2. 
 Attempts can be made to identify specific subpopulations within the greater 
parietal TCN population, which would allow for comparison of GAP-43 mRNA levels 
between these subpopulations, if they exist.  Like most pyramidal neurons, the 
neurotransmitters of TCNs are primarily excitatory, and are glutaminergic.  Some 
transcallosal neurons are glutamate negative, and these may use aspartate as a 
neurotransmitter instead.(Conti and Manzoni, 1994)  Specific stains or antibodies for 
glutamate, aspartate, peptide neurotransmitters such as the previously mentioned 
Substance P and cholecystokinin, or their metabolic precursors, could be used to identify 
transcallosal neuron subpopulations using these neurotransmitters.  Antibodies to 
different FGF-2 receptors could be used to see if there are differences in the expression of 
these receptors among different subpopulations of TCNs. 
 
4.5.5  Axon Outgrowth after FGF-2 Blockade 
 As previous studies have shown, in the central nervous system, even if GAP 
expression is successfully up-regulated following axonal injury, significant axon 
outgrowth generally does not occur in the absence of a permissive environment.(Vidal-
Sanz et al., 1987; Doster et al., 1991; Fernandes et al., 1999)  It would therefore be 
interesting to see if ipsilateral FGF-2 blockade after callosotomy can in addition to up-
regulating GAP expression, also induce axon outgrowth into and past the callosotomy 
scar site.  A variety of methods are available for assessing and quantifying neurite 
outgrowth and axon regeneration.  Histological examination with anterograde tracers 
such as biotinylated dextrane amine can be used to identify axon sprouting and the 
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generation of new growth cones and the extent of axonal regeneration across the corpus 
callosum scar can be followed over time.  The detection of specific proteins transported 
to and concentrated in growth cones beyond the scar site along the course of the 
transcallosal fiber tract could also be used to assess the extent of axon regeneration over 
time.  Candidate proteins would include GAP-43 itself and alpha-1-tubulin.(Skene and 
Willard, 1981b; Miller et al., 1989) 
 Given the known inhibitory effects of CNS glia and glial scar tissue, it is likely 
that GAP-43 induction alone would be insufficient to cause axon regeneration across a 
callosotomy scar to any significant extent.  If this is indeed the case, attempts could be 
made to promote axon growth across the callosotomy site by combining FGF-2 blockade 
with modulation of known glial inhibitors, in order to create a permissive environment 
for axon regeneration.  For example, the neutralization of the glial inhibitor nogo by the 
monoclonal antibody IN-1 has been shown to facilitate generative responses in lesioned 
CNS fiber tracts.(Bandtlow and Schwab, 2000; Qiu et al., 2000)  IN-1 could be infused 
directly into the callosotomy scar site using a second osmotic mini-pump in conjunction 
with ipsilateral FGF-2 blockade.  Alternately, the nogo receptor itself or its downstream 
signaling pathways might be inhibited.  Another substance that could be tested would be 
chondroitinase ABC (Moon et al., 2001) which has been shown to counter the inhibitory 
effects on axon regeneration of chondroitin sulfate proteoglycans produced by reactive 
astrocytes.  Other alternatives that could be tried would include implanting Schwann cells 
into the callosotomy scar, or bridging the callosotomy scar with a peripheral nerve graft. 
 
4.5.6  Transcallosal Neurons in Other Areas of Neocortex 
 The effect of bilateral FGF-2 blockade can be investigated in TCNs in areas of 
cortex other than the anterior parietal area chosen for these experiments.  Other cortical 
areas of interest can readily be investigated by changing the coordinates of the mini-
pump implantations.  More posterior parietal cortex, for example, can be targeted using 
coordinates 5.0 mm lateral to midline and 2.0 mm posterior to Bregma.   
 Motor cortex in the frontal lobe would be one area of interest for further 
investigation.  In these experiments there was a trend towards medial neurons having 
higher levels of GAP-43 expression after bilateral FGF-2 blockade that did not reach 
 90
significance.  Because motor cortex is found just medial to the parietal infusion site area 
used in these experiments, one explanation for this finding would be that motor cortex 
TCNs respond to bilateral FGF-2 blockade with a higher level GAP-43 mRNA up-
regulation, and the observed increase in mean GAP-43 mRNA expression seen in medial 
neurons is due to the presence of some motor cortex TCNs in this subpopulation.  Frontal 
motor cortex in the rat can be targeted using coordinates 3.0 mm lateral to midline and 
1.0 mm anterior to Bregma.  Motor cortex can also be differentiated histologically from 
parietal cortex because cortical layer IV is absent in motor cortex but prominent in 
parietal cortex.(Swanson, 2003) 
 Another cortical area of interest would be the cingulate cortex, which lies just 
medial to midline.  Because of the transcallosal neurons in cingulate cortex are a 
developmentally distinct subpopulation that extends midline crossing axons earlier and 
act as pioneering fibers for the remainder of the transcallosal projection, it would not be 
surprising if they had a different response to signaling molecules such as FGF-2.  With 
evidence suggesting that these neurons elaborate axons that act as pioneering fibers for 
the remainder of the transcallosal projection (Richards, 2002), it might be hypothesized 
that cingulate transcallosal neurons would possess more robust regenerative capacities, 
and perhaps retain these greater capacities into maturity.  Targeting the cingulate cortex 
with osmotic mini-pumps would be more difficult however, because the minimum lateral 
distance to midline at which bilateral mini-pumps could be implanted would be 1.7 mm 
due to the diameter of the brain infusion cannula (Alzet™).  Also, the callosotomy 
technique used in these experiments produces significant damage and scarring in the 
ipsilateral cingulate cortex, and as a result would not be suitable for experiments 
investigating cingulate neurons of any kind. 
 
4.5.7  The Mechanism of Action of FGF-2 
 The experimental results presented here leave open the question as to the precise 
mechanism by which FGF-2 produces the effect of retrograde repression.  In the adult 
CNS, FGF-2 has been found in both neurons and glia, widely distributed throughout the 
brain.(Reuss and von Bohlen und Halbach, 2003)  We confirmed the presence of FGF-2 
in parietal cortex using Western blot.  The specific neuron and glial cell populations 
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producing FGF-2 in the cortex can be identified with in-cell Western blot and in situ 
hybridization of FGF-2 mRNA. 
 Four FGF receptors have been characterized to date.(Yazaki et al., 1994; 
Chadashvili and Peterson, 2006; Maric et al., 2007)  All four receptors are tyrosine 
kinases, and FGF-2 demonstrates high affinity for all of them.(Reuss and von Bohlen und 
Halbach, 2003)  In the adult CNS, FGFR1 has been found in neurons(Leadbeater et al., 
2006) while FGFR2 has been found in astrocytes.(Chadashvili and Peterson, 2006)  
FGFR3 has been reported to be expressed in glial cells diffusely throughout the brain, 
and FGFR4 does not appear to be expressed in the mature CNS.(Yazaki et al., 1994; 
Reuss and von Bohlen und Halbach, 2003)  FGFR1 has also been associated with long-
term potentiation, memory consolidation and neurogenesis.(Zhao et al., 2007)  If the 
promotion of plasticity and retrograde repression are separate and distinct functions of 
FGF-2, then one might hypothesize that the retrograde repressive function of FGF-2 may 
be mediated by FGFR2 and/or FGFR3, though this is far from certain, because one can 
also hypothesize that the retrograde repressor should be produced directly by the target 
neuron itself, which would implicate FGFR1.  Of course it is also possible that FGF-2 
acts indirectly through a variety of paracrine and/or autocrine effects to stimulate the 
production of a second substance that acts as the direct retrograde repressor, in which 
case the action of FGF-2 in this regard could be mediated by any of the three receptors 
alone or in combination. 
 To determine which of these receptors are responsible for the retrograde 
repression effect of FGF-2, bilateral infusions of function blocking antibodies, or other 
inhibitor, of these receptors can be infused using the same experimental methods 
described here, either individually, or in combination, to determine if the elevation of 
GAP-43 expression seen with FGF-2 blockade can replicated by FGFR blockade.  
Another possible target of investigation would be heparin sulfate proteoglycans, which 
act as co-receptors.(Leadbeater et al., 2006) 
 Second messenger systems implicated in FGF-2 signaling include PLCγ, src, Crk, 
SNT-1/FRS2.(Reuss and von Bohlen und Halbach, 2003)  Also, cyclic AMP has been 
shown to play a role in GAP-43 expression and axon outgrowth in both the CNS and 
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PNS.(Andersen et al., 2000a; Andersen et al., 2000b)  All of these pathways constitute 
promising candidates for future investigations. 
 
4.5.8  The Effect of Bilateral FGF-2 Blockade on Non-transcallosal Neurons 
 One interesting incidental finding of our experiments was the observation of 
neurons that displayed high silver grain density, suggesting high GAP-43 mRNA 
expression, that were not labeled with the retrograde fluorescent dye as TCNs.  The 
identities of these neurons remain an open question.  Some of them are likely to be TCNs 
that, for whatever reason, were not labeled successfully by the fluorescent dye.  Others 
may belong to other neuron subpopulations that are sensitive to FGF-2.  It would be 
expected, if our hypothesis is correct, that interneurons with all their axon targets in the 
local cortical area that utilize FGF-2 as a retrograde repressor should display elevated 
levels of GAP-43 mRNA expression even with an ipsilateral FGF-2 blockade, and such 
neurons may account for some of the minority of neurons that were found to have 
apparently elevated GAP-43 mRNA expression in all experimental sub-groups with 
ipsilateral or bilateral FGF-2 blockade.  Also, a small number of neurons may have had, 
by chance, all their axon collaterals on both sides of midline injured as a result of the 
tissue damage caused by the bilateral mini-pump cannulae, and these neurons may have 
responded to the injury by up-regulating GAP-43 mRNA expression.  Finally, there may 
exist a small population of neurons in the parietal cortex with constitutively elevated 
levels of GAP-43 mRNA expression regardless of the effects of FGF-2. 
 Nevertheless, our qualitative observations seem to indicate that the number of 
non-transcallosal neurons that up-regulate GAP-43 mRNA expression and the magnitude 
of the up-regulation are both substantially increased in response to bilateral FGF-2 
blockade.  This raises the possibility that our observed response to bilateral FGF-2 
blockade is not specific to transcallosal neurons, but instead may be a general response of 
many different types of cortical neurons.  However, the fact that the response of non-
transcallosal neurons, like that of the TCNs, was much stronger with bilateral FGF-2 
blockade than unilateral FGF-2 blockade means that the responding non-transcallosal 
neurons must have a mechanism for the communication of signals and the coordination 
of responses across the midline.  The strongest candidates available for providing this 
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mechanism are the TCNs themselves.  A reasonable hypothesis worth testing would be 
that, as part of their overall response to bilateral FGF-2 blockade, TCNs mediate 
secondary signals that result in the up-regulation of GAP expression in other 
neighbouring cortical neurons.  These signals may potentially be transmitted via 
anterograde local axon connections, by the secretion of diffusible paracrine factors, or 
through glial intermediaries, among other possibilities. 
 
 
4.6  CONCLUDING THOUGHTS 
 In these experiments, retrograde repression has been demonstrated, for the first 
time that the author is aware of, to function in the adult mammalian CNS, supplementing 
previous evidence for this mechanism in the PNS(Bisby, 1988; Schreyer and Skene, 
1993) and embryonic central nervous system. (Karimi-Abdolrezaee and Schreyer, 2002).    
Unlike the many previously elucidated glial based mechanisms of regeneration inhibition, 
retrograde repression is primarily a neuronal mechanism.  The effects of retrograde 
repression are dependent on neuronal properties and morphology.  The localization of the 
retrograde repressive effects to the specific target tissues of the neuron in question 
strongly suggests that the neuronal synaptic targets themselves are involved in mediating 
the repressive signal.  It is not yet clear whether or not the repressive signal is sent 
directly from the post-synaptic to the pre-synaptic neuron, or indirectly through 
associated glial cells perhaps responding to primary signals from the post-synaptic 
neuron. 
 A significant change in gene expression was observed in these experiments after 
the cortical infusion of a single pharmacological agent.  If our findings are supported by 
further investigation, this has significant implications for the possibilities of future 
clinical intervention.  The implantation of devices capable of delivering controlled doses 
of pharmacological agents into precise locations even deep within the brain is readily 
achievable with modern neurosurgical technique.  On the other hand, our results also 
imply that it might be necessary to manipulate the microenvironments of multiple areas 
of the CNS distant to the injury site in order to promote the regeneration of CNS axons 
after trauma.  For example, in order to overcome the effect of sustaining collaterals in the 
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corticospinal tract if one were trying to promote axon regeneration after spinal cord 
injury, it might be necessary to target all the axon collaterals of the involved neurons in 
the motor cortex, which terminate in disparate sites throughout the central nervous 
system which may include adjacent cortical areas, the basal ganglia, and the brainstem.  
Nevertheless, this kind of stereotactic targeting of multiple sites, while technically 
challenging, is not, in theory, infeasible. 
 Another intriguing speculation is the question of whether or not the effects of 
pharmacologic manipulation may be replicated in whole or in part by electrical 
stimulation.  This would open up a whole realm of possibilities with regards to functional 
neurosurgery and the implantation of electrodes into axon target sites with the attendant 
advantages of programmability and reversibility. 
 Of course, manipulating retrograde repression alone is unlikely by itself to result 
in clinically significant functional outcomes, and promoting desirable gene expression is 
only the first step of the many required to achieve successful axon regeneration.  The 
glial mechanisms of growth inhibition must also be addressed.  Any successful future 
treatment for central nervous system axonal injury will likely be multidirectional and 
aimed at a wide range of targets, both physical and biochemical. 
 Finally, in addition to the role it plays in limiting axonal regeneration in the adult 
CNS, retrograde repression likely plays important roles in the establishment of neuronal 
circuitry during development and the modulation and regulation and neuronal plasticity 
in maturity.  Further study of this mechanism holds the promise of shedding new light on 
all of these subjects. 
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APPENDIX A 
SOLUTION RECIPES 
 
General Stock Solutions 
 
 4% Paraformaldehyde 
  For 1 L: 40 g paraformaldehyde 
    500 mL distilled water 
    500 mL 2X PBS 
  1. Dissolve paraformaldehyde in water while heating to 70°C. 
  2. Add 10N NaOH dropwise until solution is clear 
  3. Add 2X PBS 
  4. Filter to remove suspended particles 
 
 
 Phosphate Buffer Stock (PB) 
  30.8 g NaOH 
  134.6g NaH2PO4⋅H2O 
  Double distilled water up to 2 L 
 
  1. Dissolve NaOH first 
  2. Adjust final pH to 7.4 
 
 Phosphate-Buffered Saline (PBS) 2X 
  17.0 g NaCl 
  1 L PB 
  Double distilled water up to 2 L 
 
 
 1 M Tris-HCl  pH 7.6 
  121.1 g Tris base 
  800 mL water 
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  60 mL HCl 
 
 500 mM EDTA 
  1.86g EDTA 
  10 mL water 
  0.2 g NaOH, adjust to desired pH 
 
 Proteinase K stock  20 mg/mL 
  5 mL sterile water 
  100 mg proteinase K 
 
  Store at -20°C in 200 µL aliquots 
 
 Proteinase K  20 µg/mL 
  For 200 mL: 10 mL 1M Tris-HCl  pH 7.6 
    2 mL 500 mM EDTA 
    200 µL proteinase K stock  20 mg/mL 
    188 µL double distilled water 
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In Situ Hybridization Solutions 
 
 Hybridization Cocktail 
  50 mL deionized formamide 
  20 mL 20X SSC 
  1 mL 100X Denhardt’s Solution 
  10 mL 0.2M NaPO4  pH 7.0 
  10 g dextran sulfate 
  5 mL 20% sarcosyl (Sigma L5125) 
 
  1. Dissolve while stirring 
  2. Add sarcosyl last to avoid foaming 
  3. Filter through 0.45 µm filter 
  4. Store at -20°C in 5 mL aliquots 
 
 SSC (20X) 
  175.3 g NaCl dissolved  
  88.2 g Na citrate 
  1L double distilled water 
 
  1. Dissolve NaCl in 800 mL double distilled water 
  2. Add Na citrate 
  3. Adjust pH to 7.0 with 10N NaOH or HCl 
  4. Add double distilled water to 1 L 
  5. Autoclave 
 
 Deionized Formamide 
  Formamide (Fischer Scientific) 
  Mixed bed ion exchange resin (Biorad AG 501-X8 
 
  1. Gently stir required volume of formamide with ion exchange resin 
   (1 g exchange resin per 10 mL formamide) 
  2. Store at -20°C in 5 - 15 mL aliquots 
 
 Denhardt’s Solution (100X) 
  5 g Ficoll (Sigma, molecular biology grade) 
  5 g polyvinylpyrollidone (Sigma, molecular biology grade) 
  5 g Bovine Serum Albumin (Pentax Fraction V) 
  Double distilled water to 250 mL 
 
  1. Filter through 0.45 µm Nalgene filter 
  2. Store at -20°C in 2.5 mL aliquots 
 
 5 M Dithiothreitol (DTT) 
  15.45 g DTT (Sigma, molecular biology grade) 
  20 mL 0.01 M Na acetate, pH 5.2 
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  1. Dissolve DTT in Na acetate 
  2. Filter through 0.45 µm Nalgene filter 
  3. Store at -20°C in 1 mL aliquots 
  4. Do not autoclave any solutions containing DTT 
 
 Salmon Sperm DNA (Sigma D 1626) 
 
  1. Dissolve salmon sperm DNA in 100 mL water treated with DEPC 
  2. Seal with parafilm and stir overnight at room temperature 
  3. Aliquot into 1 mL volumes in sterile Eppendorf tubes 
  4. Sonicate to disrupt DNA 
  5. Store at -20°C 
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Western Blot Solutions 
 
 Whole Cell Extract Lysis Buffer 
  Final Concentration   For 100 mL 
  20 mM HEPES pH 7.5  2 mL 1 M stock 
  50 mM KCl    1.7 mL 3 M stock 
  10% glycerol    10 mL 100% stock 
  0.5 mM EDTA (RNAse free)  100 µL 0.5 M stock 
  0.5 mM EGTA (RNAse free)  100 µL 0.5 M stock 
  1 mM DTT    100 µL 1 M stock 
  1X Anti-protease cocktail (Sigma) 1 mL 100X stock 
 
  1. Add DTT prior to use. DTT remains active up to 3 months frozen 
  2. Store at -20°C to -80°C 
 
 Polyacrylamide Gel Tank Buffer 
  12 g Tris Base 
  57.6 g glycine 
  4 g SDS 
  Deionized water to 4 L 
 
 Sample Loading Buffer (1X) 
  1 mL 10% SDS 
  0.1 mL 1 M Tris  pH 7.5 
  2.0 mL glycerol 
  6.9 mL deionized water 
  Add a few crystals of bromophenol blue 
 
 Gel Solution A 
  61.2 g Tris Base 
  11.05 g Tris-HCl 
  0.92 mL TEMED 
  Add deionized water to 400 mL 
 
  pH to 8.9 with HCl 
 
 Gel Solution B 
  12.1 g Tris Base 
  1.6 mL TEMED 
  Add deionized water to 200 mL 
 
  pH to 6.9 with HCl 
 
 Running Gel (12%) 
  For 1-4 gels: 
   15 mL Gel Solution A 
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   18 mL 40% acrylamide/1.2% Bis 
   0.6 mL SDS 
   26.4 mL deionized water 
 
   Degas under vacuum (do not allow to foam) 
 
 Stacking Gel 
  For 1-4 gels: 
   2.5 mL Gel solution B 
   2 mL 40% acrylamide/1.2% Bis 
   0.2 mL 10% SDS 
   2 mL glycerol 
   13.3 mL deionized water 
 
   Degas under vacuum (do not allow to foam) 
   May use half volumes for 1 to 2 gels 
 
 Overlay Solution 
  2 mL Gel solution A 
  0.16 mL 10% SDS 
  14 mL deionized water 
 
  Degas under vacuum (do not allow to foam) 
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APPENDIX B 
MISCELLANEOUS PROTOCOLS 
 
Cresyl Violet Nissl Stain 
 
 Prepare Cresyl Violet solution 0.1% by weight Cresyl Violet in water with 3% 
glacial acetic acid.  Filter prior to use. 
 
 Dip slides sequentially in: 
 
 1. Cresyl Violet solution:  2 minutes 
 2. Distilled water: 30 seconds 
 3. 50% EtOH: 30 seconds 
 4. 75% EtOH: 30 seconds 
 5. 100% EtOH: 30 seconds 
 6. Xylene: 2 minutes 
 
 Mount slides with Permount or Entellan™ 
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Polyacrylamide Gel Electrophoresis 
 
 1. Assemble gel plates and prepare apparatus 
 2. Add ammonium persulfate to running gel (120 µL in 60 mL) and overlay 
solution (200 µL in 16 mL) 
 3. Pour running gel to height of 5.5 cm 
 4. Gently float 1 mL overlay solution on top of running gel 
 5. Allow to polymerize, pour off overlay, rinse gel top with water 
 6. Add ammonium persulfate to stacking gel solution (200 µL in 20 mL) 
 7. Pour stacking gel, insert comb 
 8. Allow to polymerize, remove comb 
 9. Install gels in tank, cover with tank buffer 
 10. Load samples 
 11. Run at 120V to 200V until blue dye just moves off bottom of gel (0.5 to 1 h) 
  
